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ABSTRACT
DRIED WHOLE PLANT ARTEMISIA ANNUA AS A NOVEL ANTIMALARIAL
THERAPY
SEPTEMBER 2014
MOSTAFA AHMED ELFAWAL, B.Sc., AIN SHAMS UNIVERSITY
M.S., AIN SHAMS UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Stephen M. Rich
Malaria is one of the worst vector-borne parasitic diseases in the developing
world. The World Health Organization (WHO) estimated that 215 million cases of
malaria occurred, with >655,000 deaths; half the world’s population is at risk of
contracting the disease. Drugs are primary weapons for reducing malaria in human
populations. Successful drugs are highly efficacious and inexpensive to manufacture
synthetically. However, emergence of resistant parasites has repeatedly curtailed the
lifespan of each drug that is developed and deployed. Currently, the most effective antimalarial is artemisinin, which is extracted from the leaves of Artemisia annua. Due to
poor pharmacokinetic properties and prudent efforts to curtail resistance to
monotherapies, artemisinin is prescribed only in combination with other anti-malarials
composing an Artemisinin Combination Therapy (ACT). Low yield in the plant, and the
added cost of secondary anti-malarials in the ACT, make artemisinin costly for the
developing world. As an alternative, we compared the efficacy of oral delivery of whole
plant (WP) A. annua to a comparable dose of pure artemisinin in a rodent malaria model.
We found that WP reduces parasitemia at least five fold more effectively than a
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comparable dose of purified drug, slows the evolution of malarial drug resistance in
Plasmodium chabaudi infected mice, and is effective against already resistant
Plasmodium yoelii (ART). This increased efficacy may result from the increase in the
bioavailability of artemisinin in the blood of mice fed the whole plant, in comparison to
those administered synthetic drug. When accompanied by plant material, more
artemisinin enters the blood stream, demonstrating a beneficial effect of the plant matrix
on the bioavailability of artemisinin. Increased efficacy and resilience against drug
resistance may result from the synergistic benefits of other anti-malarial compounds in A.
annua, such as flavonoids and terpenoids. Although effective against Plasmodium,
neither WP nor artemisinin and artesunate are effective against Babesia microti. The
differential response of B. microti and Plasmodium to artemisinins is likely the result of
significant differences in their cell biology and metabolism of hemoglobin. Welltolerated, and compatible with the public health imperative of forestalling evolution of
drug resistance, inexpensive, locally grown and processed whole plant A. annua therapy
might prove to be an effective addition to the global effort to reduce malaria morbidity
and mortality.
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GENERAL INTRODUCTION

For centuries, plant based therapies dominated medical practices in the ancient
civilizations of Africa, Asia and South America and till today in many parts of the world
where western medicine is scarce and herbal remedies are the only effective means to
treat or prevent diseases (1). Modern, Western medicine dismisses these therapies for the
most part as arcane remnants of a pre-enlightened era of modern drug design. From this
predominant reductionist world view, therapies lacking precise explanation of the
interaction of chemical moieties are not to be trusted. But like all reductionist reasoning,
this view unnecessarily simplifies the complexity of the problem and ignores the context
by which herbal remedies—not to mention the plants from which they are derived—have
evolved. In the present study, we present empirical evidence of superior efficacy of an
herbal remedy that outperformed it pseudo-pharmaceutical counterpart, which is the
primary favored anti-malarial drug at this moment. We explain this observation in the
proper evolutionary context, demonstrate the propensity for the herbal therapy’s
increased resilience, and outline a new paradigm that leverages rather than ignores
cultural and evolutionary history.
Plants possess defensive physical barriers including their cuticle and cell walls
that help them to avoid being overcome by herbivores and pathogens. Despite such
physical barriers, some pathogens have developed invasion mechanisms to penetrate into
plant’s inner tissues through wounds and/or stomata. Parasitization puts selection
pressure on these plants to evolve more advanced and complex chemical defenses to
overcome infection. In turn, plant chemical defenses puts selection pressure on pathogens
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to evolve counter-resistance mechanisms that circumvent plant defenses. This creates the
circumstance of classical “arms race”, and this particular interaction between plants and
pathogens is one of the oldest evolutionary conflicts in nature. In plants, this has lead to
evolution of complex array of chemical defenses.
Plants and animals have faced similar microbial enemies throughout their
evolutionary histories and through convergence they have evolved similar systems of
innate immunity whereby host cell receptors detect pathogen-associated molecular
patterns and activate defense responses (2). Studies on plants, humans, mice and insects
revealed evolutionary conservation in recognition of Pathogen-Associated Molecular
Patterns (PAMPs) by extracellular Pattern Recognition Receptors (PRRs) across
kingdoms (3, 4). The general elicitors of innate immunity in vertebrates—
lipopolysaccharides, peptidoglycan, eubacterial flagellin, unmethylated bacterial DNA,
glucans, chitins, and mannans—comprise the same set of molecules known to elicit plant
defense responses (3-7).
To defend against pathogens, early land plants developed PRRs to recognize
PAMPs and activate PAMP-Triggered Immunity (PTI). Through millions of years of
interaction with pathogens, plants have been able to detect and recognize molecular
patterns that are highly conserved across a broad range of microbes and essential to
pathogen survival, such as lipopolysaccharide, peptidoglycan, flagellin (a flagellum
protein), chitin, and fungal ergosterol (8). The recognition of PAMP's by PRR's activates
PTI through a suite of activations and inductions that results in transcription of defense
genes. The results of these transcriptional changes include physical effects such as callose
deposition, cell death, stomatal closure (9, 10) as well as chemical effects including
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production of reactive oxygen intermediates, antimicrobial proteins, and antimicrobial
secondary metabolites.
PAMPs are conserved and indispensible epitopes for which mutations tend to be
deleterious, hence microbes evolved resistance mechanisms by secreting effector proteins
that suppress PTI in their host plants (4, 9, 10). Effector proteins are diversely produced
by vast variety of microorganisms including bacteria, fungi, and viruses. Effector
proteins are essential for pathogen invasion, growth and development since they
enzymatically target plant cells to modify defense proteins leading to escape from host
recognition. In response to effector proteins, plants have evolved specialized Effector
Triggered Immunity (ETI) such as pathogen-Resistance (pR) proteins that recognize
microbial effector proteins and/or detect pathogen-induced modification of self-proteins.
pR proteins activate pathways that are ultimately responsible for a plant's pathogensresistance phenotype, including production of further synthesis of a repertoire of
antimicrobial secondary metabolites.
The evolution of secondary metabolites
The evolutionary rate in microorganisms is greater than in comparatively longlived plants. How do plants overcome such a disadvantage in evolutionary rate? One
means of overcoming fast evolving microorganisms is by the evolution of somatic broadspectrum pR proteins that detect any damage or modification in PTI-associated proteins.
Such indirect interaction with microorganisms enabled several pR proteins to provide
protection against a diverse group of pathogens (2).
Another strategy that enables plants to compensate for their lower evolutionary
rate is the continuous evolution, generation and retention of secondary metabolites. In
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contrast to primary metabolism where high specificity of enzymes is favored to reduce
costs associated with the production of non-essential end products (11), fitness
advantages may be conferred for producing enzymes of secondary metabolism with
lower specificity (10). To be effective, secondary metabolites must randomly intercalate
into essential and conservative enzyme sites found in a broad range of microorganisms,
hence the ability interact with multiple substrates is favored (12).
To offset costs of maintaining such diverse and non-specific secondary
metabolism, plants have catalytic flexibility in which one enzyme is able to produce
many products from one substrate (11). Such catalytic flexibility enabled plants to
generate exceedingly diverse repertoires of secondary metabolites that play important
roles in plant defense against microorganisms. Examples of such catalytic flexibility are
found in sesquiterpene biosynthesis in which one enzyme produces 34 different products
from a single substrate while in another instance the enzyme produces 52 products from a
single precursor (11). Through evolution, plants have acquired a matrix of antimicrobial
secondary metabolites marked by synergism among its components (13, 14). Natural
selection favors the sequential increase of metabolic diversity and retention of secondary
metabolites units into the chemical matrix until the marginal cost of producing additional
metabolites outweighs their benefits (15).
Through their shared evolutionary history with microorganisms, plant and animal
defense mechanisms have been refined against conserved and functionally indispensable
components of microorganismal pathogens. Plant and animal immune systems evolved
independently but in parallel given the commonality of the microbial pathogens in their
aim. These parallels have resulted in some remarkable convergences, and it is therefore
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not surprising that some of these defenses evolved in one kingdom should prove
efficacious against microbial agents targeting the other kingdom. This conserved
evolution is the basis and rational for a new approach to developing therapies to combat
human pathogens. In particular, we assert that certain plant secondary metabolites, which
evolved to protect against plant pathogens, provide the basis exploring novel therapies
against human pathogens.
Animals Self-medication
Many animal species may exploit the antimicrobial properties of plant secondary
metabolites for use against their own pathogens through evolved self-medication
behavior. Self-medication is innate behavior in many insect species including the fruit
fly, honeybee, wooly bear caterpillar and monarch butterfly (16). Using medicinal plants
against microorganisms reduces the animal’s immunity costs through reliance on the
plant’s matrix of antimicrobial secondary metabolites (16, 17). Self medication behavior
in humans and non-human animals may be explained by two hypothesizes, social
learning and natural selection (18).
Here we define self-medication in an infectious system as the circumstance where
none species (self-medication host) is infected by a second species (pathogen) and ingests
a third species (typically a plant) in direct response to that infection. To consider selfmedication behavior as an adaptation arising by natural selection several conditions must
be met.
1. Host must ingest a the material (eg. plant) in direct response to infection,
2. Ingestion should not occur in uninfected host individuals,
3. Ingestion must increase the fitness of infected hosts relative to infected host that
do not ingest, and
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4. Behavior must be innate and heritable; i.e. not learned through classical
reinforcement or taught through social interactions.

The presumptive targets of this natural selection are the physiological aspects of
sensory reception, eg. taste and olfaction. For example animals seek sodium containing
substances using specific appetite for sodium that is immediate and requires no
experience of previous deficiency. Such behavior appears innate and totally taste-guided
(19). Analogous of salt-taste marker, medicinal plants generally have distinctive volatile
fragrance, rough surface and bitter taste that may serve as cues for animals adapted to
self-medicate (20, 21). Many plant antimicrobial secondary metabolites are often
distasteful and bitter taste that also may be used as taste marker (18). Hart (2005)
reviewed the taste of a range of medicinal plants and found the majority of them have
bitter or astringent taste (18). Generally mammals dislike and reject bitter dietary foods,
hence the shift in taste receptors to tolerate (or even prefer) bitterness upon infection,
could be the specific adaptation responsible for self-medication. Examples of this
stringent model of adaptation are limited, but there are tantalizing glimpses such as the
observation that sick chimpanzees were unable to detect bitter substrate inserted into their
food while healthy ones were able to detect the bitter taste and rejected such food (22).
Because, infection associated with disease causes dramatic changes in the
physiology and/or the behavior of infected individual, natural selection could favor the
condition in which sick individuals deviate from their regular diet if such dietary
deviation gives a direct fitness advantage. This could occur either by behavioral changes
that drive sick individuals to ingest non-regular diet or by physiological changes that
thwart their sensory capability to discern and/or avoid bitter plants (18). This model
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fulfills the first two requirements for demonstrating self medication behavior as adaptive.
The actual conditions under which this would occur nonetheless require a balance of
complex trade-offs since the aversion to bitter taste is presumably an adaptation itself to
avoid toxicity. Therefore, subduing that protective behavior must lead to anti-pathogenic,
anti inflammatory, immunomodulatory, or analgesic benefits that outweight risks of
intoxication from the medicinal source or other non-medicinal, bitter tasting diet items.

Chimpanzees and bonobos use medicinal plants such as Veronica spp. to treat
gastrointestinal illnesses and Aspilia spp., Rubia spp. and Manniophyton spp. to expel
internal worms (16). Baboons use Balanites spp. to control schistosomiasis (23). Wood
rats and starlings use Umbellurlaria spp. and Agrimonia spp. to kill nest-borne fleas and
mites, respectively (24). Neanderthals used herbal remedies to treat diseases and to
manipulate disease symptoms about 60,000 years ago (18).
From this view we may speculate that animals' anti-microbial defenses against
microorganisms evolved in the presence of medicinal plants, so that animals lacking
assistance from the matrix of plant secondary metabolites would not have optimal
defenses. In this sense, use of single–compound pharmaceuticals against pathogenic
microorganisms may actually relax challenges to those microorganisms trying to evolve
ways of circumventing barriers to their proliferation.
To be certain, herbal remedies based upon plant secondary chemistries should not
be accepted as efficacious without rigorous evaluation. However they also should not be
discounted out-of-hand simply because they were not designed from a modern
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biochemical perspective nor even when they may possess emergent properties that defy
our specific ability to identify their mechanisms.
Study Systems
Parasitic protists in the phylum Apicomplexa are a large group specialized in
parasitizing animal cells. They use the unique apical complex structure, for which the
phylum is named, to penetrate host cells. Apicomplexan parasites are of great importance
to society because they are the causative agents for many of human and domestic animal
diseases. The phylum includes parasites of humans (Plasmodium, Babesia, Toxoplasma,
Cryptosporidium, Isospora), and domesticated animals (Theileria, Babesia, Sarcocystis,
Neospora, and Eimeria).
Among apicomplexan parasites, malaria is the worst vector-borne parasitic
disease in the developing world. The World Health Organization (WHO) estimated that
215 million cases of malaria occur each year, with >655,000 deaths; and half of the
world’s population is at risk of contracting the disease (25). Only five species of
Plasmodium parasites are known to infect humans: Plasmodium falciparum, P. vivax, P.
ovale, P. malariae, and P. knowlesi. Among the five species, P. falciparum is the most
deadly and responsible for more than 90% of annual deaths, followed by P. vivax.
Humans contract the disease after being bitten by female anopheles mosquitoes, which
release the infectious sporozoites into circulating blood where they travel to the liver and
invade hepatocytes. Within the hepatocytes, the parasite begins asexual replication (exoerythrocytic schizogony), producing thousands of small merozoites that each invade a
single red blood cell (RBC) and start the erythrocytic schizogony, producing about 20
small merozoites each. After maturation, the infected RBC's rupture, releasing the new
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merozoites to invade new RBCs. These erythrocytic cycles result in the majority of
malaria disease symptoms including anemia, fever, headache, splenomegaly, and hepatic
and renal dysfunction. In falciparum malaria, the parasites export parasitic proteins to the
surface of infected red blood cells, causing them to block small capillaries in the infected
patient’s brain, resulting in neurological symptoms, coma, and sudden death (26). Some
merozoites develop into sexual gametocytes within RBC's. If the patient is bitten by
another mosquito, these gametocytes are imbibed with the bloodmeal. Once in the
mosquito’s midgut, the male and female gametocytes fuse together, forming motile
zygotes that penetrate the midgut wall and settle in the basal lamina, forming oocysts.
Within the oocysts, the parasite undergoes asexual replication, producing thousands of
sporozoites. Mature oocysts rupture, releasing thousands of sporozoites into the
mosquito’s hemolymph. From the hemolymph, sporozoites migrate to the insect's
salivary glands, from which they infect human hosts when the mosquito next feeds.
Like Plasmodium, Babesia invades erythrocytes, has an invertebrate vector, and
the symptoms of the two diseases are similar, including fever, flu-like symptoms, chills,
headache, anemia, hemoglobinuria, and myalgia. In regions where malaria is endemic,
co-infection with Babesia parasites have been observed, and babesiosis may be
misdiagnosed as malaria (27). To date seven species of Babesia have been found to cause
human babesiosis Babesia microti, B. divergens, B. bovis, B. canis, B. duncani, B.
venatorum and Babesia KO1 (28). Babesia has infected increasing numbers of humans
in recent years due to greater medical awareness and increased numbers of
immunocompromised patients (28). Among all Babesia spp., B. microti causes most of
human cases in United States (28).
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Antimalarial chemotherapy
The fight against malaria predates the discovery of its causative agents. Periodic
fevers associated with swamps and marches have been known since Hippocrates and
were treated with herbal remedies. Two main herbal remedies, cinchona bark and
qinghao (Artemisia annua), were used to treat malaria for hundreds of years. In western
countries, cinchona bark has been known to treat swamp fever since 1640. In 1820,
quinine was isolated from cinchona bark and used to treat malaria-like fever. Quinine was
the first purified compound used against human disease (29). In the 1880's, the causative
agent of malaria was discovered, although the role of the anopheles mosquito in malaria
transmission was not discovered until the 1890's.
The fight against malaria entered a new era in which synthetic compounds were
used to combat parasites. In the1890's, Paul Ehrlich successfully treated two malaria
patients using methylene blue and launched his "magic bullet" concept, the idea that a
chemical compound could be made which selectively targeted a disease-causing
organism. Methylene blue was the first synthetic compound to be used against human
disease (29). Ehrlich’s "magic bullet" concept was embraced in the search for new
remedies for malaria. Some sixteen thousand synthetic compounds were tested against
malaria parasites, but very few were effective against malaria (29). In 1934, chloroquine
was developed and used in the fight against malaria. Chloroquine was both safe for
humans and very effective against malaria parasites. Around that time, many purified and
synthetic compounds were employed to treat human diseases, with herbal and natural
remedies falling out of mainstream medical use.
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In the 1950's the WHO launched the Global Malaria Eradication Program
(GMEP), through which they hoped to eradicate malaria parasites using two main
synthetic compounds, chloroquine as an antimalarial and Dichloro Diphenyl
Trichloroethane (DDT) as an insecticide against mosquitos. Chloroquine was used on a
wide scale as prophylactic treatment. However, although chloroquine was highly
effective, it lacked resilience against drug resistance. The emergence and spread of
chloroquine resistant malaria parasites and DDT resistant mosquitos were the main
reasons for the demise of GMEP in the 1960's.
Malaria parasites were among the first pathogenic organisms to develop drug
resistance against curative agents. After chloroquine’s failure, many antimalarial
compounds were deployed as monotherapy against malaria parasites; unfortunately, the
effectiveness of each of these treatments was compromised by the emergence of drugresistant parasites.
In the 1970's artemisinin was isolated from A. annua and found to be effective
against malaria parasites resistant to chloroquine. In spite of its activity in fighting
malaria parasites, artemisinin has low pharmacokinetic properties. To increase its
pharmacodynamic and pharmacokinetic properties and to slow the evolution of drug
resistance, the WHO recommended using artemisinin derivatives, mainly artesunate, in
combination with other antimalarial drugs. The low yield in A. annua and the additive
cost of partner drugs make the WHO-endorsed Artemisinin-based Combination Therapy
(ACT) unaffordable for many people in developing countries. It was hoped that use of
ACT would minimize risk of drug resistance. However, in 2005, the earliest evidence of
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P. falciparum resistance to ACTs was found in Southeast Asia (30-34). The fight against
malaria became critical again, as no affordable replacement for ACT was available.
Hypothesis
Plants have evolved complex matrices of secondary metabolites—produced as a
response of PTI and ETI upon recognition by PAMPs and pR proteins respectively—that
target conserved functions, and structural elements of invading microorganisms and
animal herbivores. Such broad-spectrum defense is observed in many medicinal plant
species for which the secondary metabolites matrix that has broad biological activity
against multiple taxonomic groups. For example, in A. annua and artemisinin are known
to have activity against bacteria, protozoa, viruses, arthropods, and other plant species
(35-39). Synergism between the biological activities of artemisinin and other A. annua
secondary metabolites results in a range of ecological effects, from allelopathic activity
against other plants to antimalarial activity against animal disease.
A. annua is regarded as safe for human consumption and has been widely
consumed in many parts of China for more than 2000 years (29) and was a known herbal
treatment for fevers symptomatic of malaria (40). Recently, several reports have
described synergism between artemisinin and other A. annua flavonoids. These include
antimalarial activity of A. annua constituents other than artemisinin-- including other
terpenes and flavonoids-- and increased bioavailability of artemisinin when delivered in
plant form. Based on such reports, we hypothesized that the complex matrix of secondary
metabolites present in the dried whole plant A. annua material may be used directly
against malaria parasites, thereby saving the high cost associated with artemisinin
isolation and purification. Because A. annua has been successfully used to treat malaria-
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like fevers for more than 2000 years without development of resistance, and because of
the multiple constituents in A. annua known to have antimalarial activity, we also
hypothesized that dried whole plant A. annua may be used to treat malaria parasites
resistant to artemisinin and to delay the evolution of drug resistance.

	
  

13	
  

	
  
CHAPTER I
DRIED WHOLE PLANT ARTEMISIA ANNUA AS ANTIMALARIAL THERAPY
Mostafa A. Elfawala, Melissa J. Towlerb, Nicholas G. Reichc, Douglas Golenbockd,
Pamela J. Weathersb, Stephen M. Richa

a

Laboratory of Medical Zoology, Department of Microbiology, University of Massachusetts, Amherst, MA
01003; b Department of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester MA
01609; c Division of Biostatistics and Epidemiology, School of Public Health and Health Sciences,
University of Massachusetts, Amherst, MA 01003; d Infectious Diseases and Immunology, University of
Massachusetts Medical School, Worcester, MA 01605
Author contributions: D.G., M.A.E., P.J.W., and S.M.R. designed research; M.A.E. performed the
mouse-parasite experiments; M.J.T. and P.J.W. grew plants and conducted biochemical assays; M.A.E.,
N.G.R., and S.M.R. analyzed data; M.A.E., P.J.W., N.G.R., and S.M.R. wrote the paper (41).

Introduction:
Malaria is among the most prevalent infectious diseases in the developing world,
imposing a vast burden of mortality and perpetuating cycles of poverty. In 2009, the
World Health Organization (WHO) estimated that 225 million cases of malaria occurred,
with >780,000 deaths (42). In spite of recent advances in our understanding of this
parasite, efforts to prevent transmission have remained largely unchanged for over a
century. Though malaria vaccines hold future promise, vector control and chemotherapy
remain the primary weapons for reducing the burden of disease in individuals and
populations. Artemisinin, in the form of Artemisinin-based Combination Therapy (ACT),
is currently the best treatment option against those malaria parasites that have evolved
resistance to drugs such as chloroquine (43). Moreover, artemisenin (AN) and its
derivatives have also been shown to have effects on a number of viruses, a variety of
human cancer cell lines (35, 36), several neglected tropical parasitic diseases including
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schistosomiasis (44), leishmaniasis (45, 46), New- and Old-World trypanosomiases (47),
and many livestock diseases (48).
Current artemisinin production requires its extraction from the cultivated herb
Artemisia annua L., which as an herb is “generally regarded as safe” (GRAS) for human
consumption (49). However, considerable production costs and limited availability of
artemisinin limit its present usefulness in the campaign against malaria (50). De novo
chemical synthesis of artemisinin is neither practical nor cost-effective, and even the best
plant cultivars yield only ca. 1.5% artemisinin, and agricultural yields seldom exceed 70
kg/ha (51). The drug is solvent-extracted from plant material, crystallized, and typically
used for semi-synthesis of artemisinic derivatives. Although A. annua is relatively easy to
grow in temperate climates, low yields of AN lead to relatively high costs for isolation
and purification of the drug (52). Because of this shortcoming, plant scientists have
focused their efforts on producing cultivars of A. annua with higher artemisinin crop
yield (53). Transgenic production schemes are also underway (54, 55). Meanwhile, a
worldwide shortage fails to meet the need to treat malaria, not to mention those other
diseases against which artemisinin holds such promise (43).
One means of reducing the cost of production would be to limit the amount of
post-harvest processing by using the whole plant (WP). We wondered whether omitting
the extraction step, by using whole plant A. annua directly as the source of artemisinin,
might prove efficacious in an experimental murine model. In a previous study, we
showed that mice fed dried WP material had about 40 times more artemisinin in their
bloodstream than mice that were fed a corresponding amount of pure drug (49). This
amount exceeded by eight fold the minimum concentration of serum artemisinin required
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for a single curative dose (10 µg/L) against P. falciparum (56). This suggested that the
active ingredients were delivered faster, and in greater quantity, from whole plant
treatments than from pure drug treatments. We further hypothesized that because of the
combination of parasite-killing substances (artemisinin and flavonoids), perhaps
augmented via synergism among the constituent compounds in this plant (artemisinin and
the flavonoids: casticin, eupatorin, and chrysosplenetin) (57, 58), might render whole
plant consumption as a form of ACT.
We thus sought to determine whether WP A. annua can kill malaria parasites in
vivo using a rodent malaria model. Plasmodium chabaudi is an excellent model for the
most deadly of the human parasites, P. falciparum, because both species demonstrate
preference for mature erythrocytes as opposed to reticulocytes that are favored by other
human and rodent malaria parasites (59, 60). Rodent malaria models are invaluable for
studying modes and mechanisms of resistance to antimalarial compounds (61).
Demonstrating parasite killing using this inexpensive and resilient treatment could be an
important first step in establishing a novel therapy based on WP A. annua for treatment of
human malaria. Furthermore, it may help to identify complementary and/or synergistic
anti-malarial compounds within the plant.
Materials and Methods
Plant material. Artemisia annua L. (SAM cultivar; voucher MASS 00317314)
containing 1.48±0.06% AN (dry weight) was used in this study. To obtain adequate
amounts of leafy biomass, plants were grown in soil either in greenhouses, culture rooms,
or growth chambers under continuous light to maintain vegetative growth. Plants were
propagated by cuttings to insure that the outcrossing characteristics of A. annua did not
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result in genetic loss of AN content. When the plants reached about 0.5-1 m, they were
harvested and dried in the light at 25°C for several days. Leaves were then stripped from
stems and pulverized through a series of brass sieves ending with 600 µm meshed
powder. All dry leafy biomass was pooled, homogenized and then assayed for AN.
AN was measured using GC-MS by extracting with pentane (~6 mg/mL) and
sonicating for 30 min. Extract was decanted into glass test tubes and dried under nitrogen
gas, then stored at -20°C until analysis. Samples were resuspended in pentane and
transferred to a 1 mL vial with a 100 µL glass insert. A 1 µL injection into the GC-MS
[GC, Agilent 7890A; MS, Agilent 5975C; column, Agilent HP-5MS (30 m x 0.25 mm x
0.25 µm)] used the following oven program: ion source temperature 280°C; inlet 250°C;
initial temperature of 125°C for 1 min, then ramp to 300°C at 5°C/min, for a total time of
36 min. Ultrapure helium was the carrier gas at 1 mL min-1. Identification was via NIST
library and purchased AN standard (Sigma-Aldrich Chemical, St. Louis, MO).
Parasite information. Plasmodium chabaudi ASS (MRA-429) was obtained through the
Malaria Research and Reference Reagent Resource Center (MR4) as a part of the BEI
Resources Repository, NIAID, NIH. Tubes of blood collected from infected mice, were
removed from liquid nitrogen storage and left at room temperature for 30 minutes. A
100µL aliquot of the parasite-infected blood was mixed with 500 µL Dulbecco’s
Phosphate Buffered Saline (DPBS). To recover parasite stocks, two C57BL/6 mice were
injected intraperitoneally (i.p.) with 200 µL of the DPBS mixture. Percent parasitemia
was determined in Giemsa-stained thin blood smears days 3-7 post-infection (p.i.). Seven
days after infection, one mouse was euthanized and cardiac puncture was used to collect
blood into lithium heparin tubes. Infected blood was volumetrically adjusted by dilution
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in DPBS to create a 200 µL aliquot of 105 infected erythrocytes for infection into two
additional mice for a second round of recovery. The recovered parasites were used for
subsequent challenge and drug study. Rodent malaria models showed differences in the
degree of susceptibility among different strains of mice, as well as age related
differences. We used two mice to draw the standard parasitemia curve in the C57BL/6, 812 weeks male mice. The two mice were inoculated i.p with 105 infected erythrocytes and
parasitemia was determined in Giemsa-stained thin blood smears from day 1 to day 11
p.i. (Fig. I.1). P. chabaudi produces a self-limiting infection in laboratory mice, such that
parasites began to appear in the blood smears on day 4 p.i., reaching peak of the
parasitemia on day 8 p.i. From the standard parasitemia curve we chose to treat mice on
day 6 p.i. when the parasites commenced the log phase of growth.
Mouse feeding and drug delivery details. All mouse experiments used inbred male
mice C57BL/6, 12 weeks of age. For each experimental replicate, an aliquot of 105
infected erythrocytes was inoculated i.p. into each of 30 mice. For the first two replicates,
mice were randomly divided into three groups of ten mice per group (ANLO, WPLO, and
Control). For the third replicate, mice were randomly divided into five groups of six mice
per group (ANLO, WPLO, ANHI, WPHI, and Control). Individual mice were identified by
tail markings using permanent marker. Starting on day 3 p.i., percent parasitemia was
determined in Giemsa-stained thin blood smears from a drop of peripheral blood obtained
from the tail. Mice were observed twice daily for signs of disease stress. Food and water
were introduced ad libitum for the first five days. On day five, food was withheld for 24
hours, but water was freely available.
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Whole plant (WP) treatment consisted of dried A. annua plant powder ground and
passed through a 0.3 mm sieve, mixed with water to a final volume of 0.5 mL. Two
dosages were used: WPLO and WPHI. WPLO consisted of 0.5 mL treatment slurry
contained 40 mg dry weight (DW) of plant powder, containing 600 µg artemisinin and
corresponding to 24 mg AN/kg live body weight. WPHI consisted of 0.75 mL treatment
slurry contained 200 mg DW of plant powder, containing 3000 µg artemisinin and
corresponding to 120 mg AN/kg live body weight.
Pure drug (AN) treatment consisted of artemisinin purchased from Sigma Aldrich
freshly dissolved in DMSO and pulverized mouse chow. Two dosages were used, ANLO
and ANHI. ANLO consisted of a slurry containing 600 µg AN dissolved in 60 uL DMSO
mixed with water and 40 mg powdered mouse chow to final volume of 0.5 mL. ANLO
consisted of a slurry containing 3000 µg AN dissolved in 60 uL DMSO mixed with water
and 200 mg powdered mouse chow to final volume of 0.75 mL.
Placebo control (CON) consisted of 60 µL DMSO, mixed with water and 40 mg
powdered mouse chow to a final volume of 0.5 mL. Delivery of the appropriate 0.5 mL
treatment/control was performed immediately after dose preparation by oral-gastric
gavage into mice using a feeding needle (18G, curved, 2”, and 2.25 pall diameter). Food
and water were introduced ad libitum after gavage. Percent parasitemia was determined
every 24 hours in Giemsa-stained thin blood smears from days 3-6 p.i., then every six
hours for 48 hours post gavage, and again on 24 hour intervals for days 9-11 p.i.. All
mice were euthanized on day 11 p.i. via asphyxiation in a CO2 chamber followed by
cervical dislocation. The experiment was repeated three times.
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Statistical analyses. We fit linear mixed models to estimate and compare the average
parasitemia for each treatment group at each measured time point. Including a random
intercept for individual mice allowed us to adjust for repeated observations on the same
mouse. The primary analysis compared CON, WPLO and ANLO treatment groups to assess
statistically significant parasitemia differences in these groups at each time point (see Fig.
I.2). For the primary analysis, data from all three replicates were used. A secondary doseresponse analysis compared the CON, WPLO, WPHI, ANLO, and ANHI treatment groups at
all measured time points (see Fig. I.3). For the secondary analysis only data from the
third replicate were used.
For each model, 10,000 Markov chain Monte Carlo (MCMC) samples were
drawn from the posterior distributions of the average parasitemia levels for each
treatment group at each time point. Then, 95% confidence interval endpoints for a
particular parasitemia level were established at the 2.5th and 97.5th quantiles of the
MCMC samples for that parameter. An estimated difference between two groups was
declared “significant” if the 95% confidence interval for the difference did not cover
zero. Analyses were conducted using the statistical software R v2.15(62) and the lme4
package(63), Graphics were produced using the ggplot2 package.
Ethics Statement. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Massachusetts (Protocol# 2011-0015).
All efforts were made to minimize suffering of animals during experimental procedures.
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Results and Discussion
We found conclusive evidence that whole plant A. annua kills malaria parasites
more effectively than a comparable dose of pure drug. In our primary analysis, we
compared parasitemia over time in mice treated with either low-dose, whole plant A.
annua (WPLO), low-dose, pure drug artemisinin (ANLO), or placebo (CON). Only 24 hr
after treatment, dead parasites (with condensed dark pigment) were observed in mice
treated with WPLO ; 30 hours after treatment, parasitemia was < 0.001% (Fig. I.1). Mice
treated with WPLO showed significantly lower parasitemia than those treated with ANLO
from 12 to 72 hours post-treatment (Fig. I.2). Mice treated with ANLO did not show
significant difference in parasitemia from those administered a placebo at any time point.
In a subsequent dose-response analysis, we added high-dose comparison groups,
ANHI and WPHI. Each of the four treatment groups experienced significantly lower
parasitemia than the control mice (Fig. I.3). All mice treated with WPLO responded
strongly in the first 24 hrs following gavage, showing the lowest level of parasitemia at
30 hours pos-gavage; only 3 of 26 WPLO-treated mice (12%) had parasitemia of 3% or
greater. However, 36 hours after gavage, 38% of the WPLO-treated mice were above this
threshold. Notably, treatment with WPLO was just as effective in reducing parasitemia as
was treatment with ANHI for the first 72 hours post treatment (Fig. I.3). Thereafter,
WPLO-treated mice had significantly higher parasitemia. Although the suppression of
parasitemia was significant in the three treatment groups after a single dose treatment,
low dose WPLO resulted in faster recrudescence than either WPHI or ANHI (Fig. I.3),
suggesting that multiple treatments at this dose would be necessary for a curative effect.
Considering that a normal course of ACT treatment for human malaria currently requires
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several doses, spread over several days, a similar regime may also be effective in the case
of lower dose WP administration. Pharmacokinetics will be needed to determine serum
levels of the drug. No differences between the WPHI and ANHI groups were detected after
treatment. This is consistent with the short half-life seen in the pure drug in human
patients and the prescribed need for multiple doses per day for several days (42).

Although the precise mechanisms of its anti-malarial activity remain unproven,
artimisinin is suspected (like other drugs, including chloroquine) to interfere with heme
detoxification, a crucial requirement for parasite survival in erythrocytes. Plasmodium
parasites digest hemoglobin, producing heme as a byproduct. Free heme molecules are
toxic, so parasites sequester it in the form of hemozoin polymers in unique digestive
vacuoles. Artemisinin is a sesquiterpene lactone with a crucial endoperoxide bridge (64),
and in the presence of heme, this bridge is broken, thereby releasing free radicals harmful
to the parasite (65).
The empirical evidence for increased anti-malarial activity of WP relative to AN
might be explained by differential bioavailability of the artemisinic compounds.
Weathers et al (2011) showed that mice treated with a WP equivalent of 1.2 mg/kg AN
reached their highest concentration of artemisinin in the blood (87 µg /L) 30 min after
gavage, whereas mice treated with AN did not reach their the maximum concentration
(74 µg /L) until much later ( ≥ 60 min) (49). Moreover, poor solubility and high
metabolic breakdown of artemisinin by hepatic and intestinal cytochrome P enzymes
(CYP P450 and CYP3A4) may reduce its bioavailability when administered in pure form
(66). Infusions made from whole plant A. annua showed marked inhibition of the
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intestinal and hepatic CYP enzymes by flavonoids and/or other compounds (48). Hence,
inhibition of metabolic enzymes correlates with greater bioavailability of artemisinin,
which is consistent with our findings that WP demonstrates greater parasite killing
activity than a comparable pure drug treatment.
Whole plant (WP) A. annua may also have enhanced antimalarial activity due to
synergism among particular plant compounds and artemisinin (14, 48, 67). Among these
compounds are many flavonoids, of which at least six (artemetin, casticin,
chrysosplenetin, chrysosplenol-D, cirsilineol, and eupatorin) are of interest for their
antimalarial roles. The synergism between artemisinin and these flavonoids may be due
to their ability to potentiate the activity of artemisinin. When each of these six flavonoids
was combined individually with artemisinin, the IC50 of AN against P. falciparum
decreased by 20-50%, demonstrating an apparent synergy between the sesquiterpene
lactone, artemisinin, and those six methoxylated flavonoids (57, 58). The precise
mechanism of flavonoids in activating artemisinin is not fully understood, however it has
been reported that A. annua methoxylated flavonoids enhance the formation of the
artemisinin-heme complex (68), which increases the release of free radicals.
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Fig. I.1. Giemsa stained blood smears from mice showing erythrocytes infected with P.
chabaudi, 30 hours after treatment with (A) WPLO (24 mg/kg whole plant delivered
artemisinin), (B) ANLO (24 mg/kg pure drug artemisinin), and (C) Placebo control.
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Fig. I.2. P. chabaudi parasitemia of three treatment groups across all experimental
replicates: low-dose whole plant A. annua (WPLO, N=26 containing 24mg/kg in planta
artemisinin, and low-dose pure drug (ANLO, N=20) containing 24mg/kg pure artemisinin,
and placebo control (CON, N=23) which received only mouse chow. Dark lines indicate
average parasitemia by treatment type. Lighter lines show individual mouse trajectories.
Shaded regions indicate the 95% confidence interval for the means calculated based on
normality assumptions. Dashed vertical line indicates time of treatment.
Two other major A. annua flavonoids, myricetin and quercetin, are known to
inhibit mammalian thioredoxin reductase, which is critical for cellular redox control (69).
Thioredoxin reductase is also essential for the P. falciparum erythrocytic stage (70);
therefore, inhibition of this parasite enzyme by myricetin and quercetin may work in
synergy with artemisinin against P. falciparum (71).
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Fig. I.3. Dose comparisons of WP and AN treatments from the third replicate
experiment: WPLO (N=6) and WPHI (N=6) received 24 mg/kg and 120 mg/kg in planta
artemisinin, respectively; ANLO (N=5) and ANHI (N=6) received 24 mg/kg and 120
mg/kg pure artemisinin, respectively. Placebo control (CON, N=6) received only mouse
chow. Dark lines indicate average parasitemia by treatment type. Lighter lines show
individual mouse trajectories. Shaded regions indicate the 95% confidence interval for
the means calculated based on normality assumptions. Dashed vertical line indicates time
of treatment.
In addition to the bioavailability and potentiation attributes of WP, there are other
compounds in A. annua that may act to reduce parasitemia independent of artemisinin.
Liu et al (1992) reported the antimalarial activity of several A. annua flavonoids
delivered in vitro as isolated compounds, in the absence of artemisinin (58). Moreover,
antimalarial activity has been documented for related plant species that do not produce
artemisinin (72). Among the compounds in A. annua not yet fully investigated are more
than a dozen other sesquiterpenes, some of which have shown promise for killing
parasites in rodent models (67).
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Determining the mechanisms for increased efficacy of WP will require further
investigation, but it seems certain that the constituent compounds contained within A.
annua comprise a complex set of interactions and synergies yet to be described. Given
the complex nature of the plant and its many components, WP may not necessarily be
considered a simple monotherapy. While the temptation might be to consider WP as
merely an alternative delivery mechanism for artemisinin, our results strongly indicate
that WP is unique and may represent an innovative combination therapy. We refer to this
as a plant Artemisinin Combination Therapy (pACT). A pACT can be distinguished
from other combinational therapies where the drug components do not necessarily work
synergistically because their combinations are artificially contrived. The pACT comprises
a biologically complex entity, in which the combinations are the result of evolutionary
processes that would have attributes of redundancy and resiliency that make combination
therapies selectively advantageous to simple monotherapies. Refinements of these
combinations by evolutionary processes ensures they are robust.
The novelty of the WP pACT cannot be overemphasized as there is a common
misconception that this therapy has been tested previously. It has not. The WP therapy
tested in the present study should not be confused with tea or infusion therapy. Whole
plant A. annua (WP) tested here against murine malaria, utilizes the plant in its entirety,
dried under controlled conditions and ingested by the host. Such a preparation of A.
annua has never been tested against malaria parasites (in humans, mice or otherwise).
Because A. annua has long been used to make tea to treat fever in Asia (73),
several investigators have proposed to re-establish the use of A. annua tea for rapid
treatment of malaria (43, 74). These teas have major shortcomings. Firstly, large volumes
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of tea must be consumed over short periods to ensure adequate ingestion of drug, a
nontrivial matter considering the bitter taste of the tea, especially for pediatric patients.
Moreover, while a 5 min boiling water extraction yields about 90% of the plant’s
artemisinin (74), this is not an effective process for extracting key flavonoids (58).
Analysis of hot water tea extracts following the optimized protocol described by van der
Kooy and Verpoorte (74), showed loss of about 99% of the original flavonoids that
reportedly synergize with artemisinin (75).
Not only does WP differ from teas and infusions in terms of its efficacy and
pharmaceutical properties, but because of its preparation, it can be carefully controlled
and preserved. We was previously proposed development of a new form of anti-malarial
therapy based on dried, encapsulated A. annua leaves as an inexpensive, dose-controlled,
rapid delivery of the drug to treat uncomplicated cases of malaria and other neglected
tropical diseases for which artemisinin has been shown to be effective (49). Dosage can
be controlled because dried WP A. annua can be homogenized and assayed for
artemisinin content prior to encapsulation. Capsule size and number can be adjusted
based on artemisinin content and patient weight.
Our purpose in the present study was to determine whether this “generally
regarded as safe” (GRAS) herb (76) is effective in killing malaria parasites in vivo.
Extrapolating appropriate human dosage from experimental evidence in mouse models
will require additional investigation, however it is generally understood that this
extrapolation will not scale linearly with respect to body mass. Better indicators that
allow for allometry include use of total body surface area (77) and/or take full
consideration of physiochemical properties of the drugs and species involved (78). As an
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example of this non-linear relationship, we can look to the results from ANLO treatment
administered to mice in this study. ANLO mice received a dose of 24 mg/kg which
exceeds the current WHO single therapeutic dose (20 mg/kg) for treating human malaria,
however, in our study this dose of pure drug had very little effect against mouse malaria
parasites. This is most likely due to metabolic differences and rates of uptake of oral
drug between mice and humans.
Single oral dosages of AN proven effective against human P. falciparum malaria
range from 100-500 mg (79), which corresponds to 6-33 grams of WP assuming a 1.5%
artemisinin content. Assuming an average tablet size of 1 gram, delivery of a comparable
dose of WP seems plausible. However, our data suggest that WP requires a smaller
overall amount of artemisinin since even the WPLO effectively reduced malaria after just
a single dose. Moreover, it is important to bear in mind that while WPLO was the lowest
concentration in our study, it does not necessarily represent a minimum effective dose.
Notwithstanding challenges to be overcome and further research needed, our
preliminary investigations hold great promise for easing the burden of high cost and
limited availability currently confronting use of artemisinin-based semi-synthetic
derivatives. While production costs for pharmaceuticals are not generally made publically
available, it is possible to estimate potential savings associated with using WP vs. AN by
looking to the estimated efficiencies of processing AN from the plant. Kindermans et al
(80) estimate the yield for extraction and purification of drug from A. annua to be 5080% efficient. This is consistent with general understanding of downstream processing
costs wherein product losses increase with the number of unit operations (unit ops) (81).
All things being equal (eg. artemisinin content for a given cultivar), this would suggest a
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20-50% savings realized by forgoing the extraction and purification steps, as would be
the case for production of WP. An example of the steps involved in production of AN
from whole plant is provided by de Vries et al (1999), and compared with steps for
producing WP (82) (Fig. I.4). Current production of AN by extraction from A. annua has
seven more unit ops than the single unit op associated with direct use of the whole plant,
and this net loss in efficiency translates to higher costs per product unit (Fig. I.4). Given
the multiplicative principle of downstream processing, even if each processing step has
relatively high efficiency, the overall efficiency will be less. For example, even if each of
the seven additional steps for production of AN could be made 95% efficient, the overall
efficiency would be merely 69.8%, which means less than three quarters of the starting
material is realized as drug. Such a loss means a higher cost for the delivered drug. This
simple analysis does not even consider the additional costs for reagents, labor, and energy
that are required for processing the extract (Fig. I.4), which de Vries et al (1999)
estimated may comprise up to 22.9% of the total manufacturing costs(82). This 22.9%
represents additional cost savings for the use of WP because those inputs are no longer
required.
And while our data are far from representing a clinical trial, they do provide
preliminary indications that the WP therapy requires a far smaller dose than the
corresponding amount of pure artemisinin. Indeed, our experiments indicate that a dose
of WP has a five-fold increase in anti-malarial activity over that of the corresponding
amount of AN. This increased activity per unit of plant mass not only affects the dosing
regimen but also has profound economic impacts if the WP approach should prove useful
on a large scale to treat human malaria.
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AN process:
Dried leaves à Milling and homogenization à Extraction at 30-40°C
à Crystallization à Filtration/washing à Decolorization à
Crystallization à Filtration à Drying at 55-60°C àAN à Assay
WP process:
Dried leaves à Milling and homogenization à AN àAssay
	
  
Fig. I.4. Comparison of production processes for AN and WP demonstrated reduction in
unit operations associated with use of whole plant as therapy. (Based on de Vries et al
(1999)(82).
Much work remains to determine feasibility and efficiency of bringing whole
plant A. annua into the arsenal in the fight against malaria. Among the challenges to be
faced are some botanical obstacles, not the least of which is that this plant readily
outcrosses, making it difficult to maintain high artemisinin content in the plant using seed
saving methods which are standard agricultural practice in the developing world.
Moreover, to date all efforts at improving the A. annua crop have focused on plant
breeding and growth methods to maximize artemisinin content and in so doing to
increase efficiencies and drive down costs. The use of the whole plant as therapy may
represent a paradigm shift in this regard, since it may well be the case that effectiveness
of WP is not wholly dependent on artemisinin content. New plant breeding strategies
would have to be considered to optimize plant performance and maximize efficacy. But
the potential for an inexpensive malaria therapy that by its very nature possesses great
resilience to parasite resistance, makes this investment of effort well worth while.
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Conclusions
We have demonstrated that orally delivered WP A. annua is an effective means of killing
malaria parasites in a mouse model. An edible WP A. annua treatment approach could
significantly increase the number of patients treated and at significantly less cost. In fact,
our results suggest that the WP treatment is a more efficient delivery mechanism than the
purified drug, which is both costly and inefficient. Because AN has such broad potential
therapeutic power against many infectious agents (35), our approach would dramatically
reduce the cost of healthcare not only in developing countries, but also in more developed
nations. Furthermore, use of A. annua could be implemented locally: a plan for plant
cultivation, processing, and drug content validation was described in an earlier report
(49). This, in turn, could provide a broad socioeconomic stimulus for developing
countries while making them less dependent on the West.
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Chapter II
PHARMACOKINETICS OF ARTEMISININ DELIVERED BY ORAL
CONSUMPTION OF ARTEMISIA ANNUA DRIED LEAVES IS IN DIFFERENT
FOR HEALTHY VS. PLASMODIUM CHABAUDI-INFECTED MICE.
Pamela J. Weathers*a, Mostafa A. Elfawal*b, Melissa J. Towlera, George K. AcquaahMensahc, Stephen M. Richb
a

Biology and Biotechnology, Worcester Polytechnic Institute, Worcester MA 01609; b Laboratory of
Medical Zoology, Microbiology, University of Massachusetts, Amherst, MA 01003; c School of Pharmacy,
Massachusetts College of Pharmacy and Health Sciences (MCPHS University), Worcester, MA 01608
*Contributed equally to the work
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G.A-M. analyzed data; M.A.E., P.J.W., M.J.T., G.A-M. and S.M.R. wrote the paper (83).

Introduction
Malaria is one of the worst vector-borne infectious diseases in the developing world and
the World Health Organization (WHO) estimated that 215 million cases of malaria
occurred, with >655,000 deaths; half the world’s population is at risk of contracting the
disease (25). Artemisinin, delivered in combination with an alternate drug as
Artemisinin-based Combination Therapy (ACT), is currently the preferred treatment
against the disease in order to prevent emergence of drug resistance.

Artemisinin (AN; Fig. II.1) is produced, extracted, and purified from the “generally
regarded as safe” GRAS; (40) plant Artemisia annua L. (Asteraceae). The drug also has
shown promise against a wide variety of human (84) and livestock diseases (85); many
are common to the developing world. Although new sources of the drug are emerging
from chemical synthesis (86) and engineered microbes (87), artemisinin is currently only
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commercially available from A. annua with insufficient supply to treat malaria, let alone
other artemisinin-susceptible diseases. To obviate emergence of drug resistance, ACT codrugs are also needed, which usually increases cost (88).

Fig. II.1. Artemisinin (left) and deoxyartemisinin (right).

In an effort to improve the efficacy of artemisinin therapy and lower cost, we recently
showed that when delivered orally to Plasmodium chabaudi-infected mice, a single dose
of dried leaves of A. annua quelled parasitemia at least fivefold more than an equal
amount of the pure drug (41). Beyond the abnormalities associated with infection,
analysis of blood toxicology showed no toxicity, results consistent with some human
trials using dried A. annua leaves (89, 90). It was also previously showed that healthy
mice fed dried A. annua leaves had > 40 times more artemisinin in their bloodstream than
mice fed a corresponding amount of pure drug (49). The measured serum levels exceeded
by eight fold the minimum concentration of artemisinin (~10 µg L-1) required for lethality
against P. falciparum (56). Together these results suggested that more artemisinin was
delivered from whole plant treatments than from the pure drug treatment. Indeed, in a
recent simulated digestion study, > 50% of dry leaf-delivered AN was still available in
the intestinal digestate (91). It is thought that besides artemisinin, the combination of
other parasite-killing substances normally present in the plant (flavonoids, monoterpenes
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etc.; (92); (57); (93); (94) may be responsible for the observed responses either by
improving bioavailability and/or improving therapeutic efficacy. In short, the plant may
itself be providing endogenous combination drugs with its artemisinin. We thus termed
this a plant-based artemisinin combination therapy, hereafter referred to as pACT.

To better assess the potential of pACT, we conducted a longer pharmacokinetic study to
answer two main questions: were the pharmacokinetics of pACT different between
healthy and infected mice, and was the plant matrix critical to the appearance of
artemisinin in the blood? These results will further our understanding of how the drug
moves into the blood when orally delivered as dried leaves of the whole plant.

Materials and Methods
Plant material. Artemisia annua L. (SAM clonal cultivar; voucher MASS 00317314;
vernacular names: annual wormwood; qīnghāo; sweet annie, sweet wormwood)
containing 1.48 ± 0.06% artemisinin (dry weight) as determined by GCMS was used in
this study. Dried leaves of the SAM cultivar also contain monoterpenes (e.g., 0.21%
(w/w) camphor, 0.007% eucalyptol, 0.037% α-pinene) and flavonoids (0.37% total).
Plants were grown under controlled conditions, harvested, dried, and leaves sieved and
pulverized as previously described (41). Homogenized dried leaf biomass was assayed
for artemisinin and deoxyartemisinin using GCMS as described in Elfawal et al. (2012).
Identification was via NIST library and purchased standards of artemisinin (SigmaAldrich Chemical, St. Louis, MO) and deoxyartemisinin (Toronto Research Chemicals
Inc.).
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Mouse infection, feeding and drug delivery. Plasmodium chabaudi ASS (MRA-429)
was obtained through the Malaria Research and Reference Reagent Resource Center
(MR4) as a part of the BEI Resources Repository, NIAID, NIH. Infection of 20 inbred
male C57BL/6 mice weighing an average of 23 g was established by intraperitoneal (i.p.)
injection with 107 P. chabaudi-infected red blood cells as detailed in Elfawal et al.
(2012). A second group of 20 of these same mice served as healthy controls. Infected
(n=20) and healthy (n=20) mice received oral-gastric gavage of pACT treatment
consisting of dried, powdered A. annua leaves in a water slurry, prepared fresh, and
administered 72 hours post-infection (when parasitemia reached 2-3%) at an amount
corresponding to 100 mg AN kg-1 live body weight as detailed in Elfalwal et al. (2012).
Blood was collected by cardiac puncture from five infected and five healthy mice at each
of 4 time intervals (15, 30, 60, and 120 min post-gavage). For additional serum
comparisons, two groups of three healthy mice were individually treated with 100 mg kg1

of pure AN in DMSO and water per kg live body weight with or without mouse chow

(Elfawal et al., 2012) and blood collected at 60 min post gavage. Because a preliminary
study showed that serum AN was at best barely detectable when mice were fed the pure
drug, blood from each group of mice was pooled prior to extraction and analysis.

Blood extraction and analysis. Serum and red blood cells were separated by
centrifugation at 5,000 x g for 10 min and both fractions were immediately stored at 80°C until extraction. Samples were extracted overnight at room temperature with an
equal volume of methylene chloride. Where necessary, extracts were filtered through a
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0.45 µm filter to remove particulates. Extracts were dried under nitrogen gas at room
temperature and the dried residue resuspended in a known volume of methylene chloride
for analysis of artemisinin and deoxyartemisinin by GCMS. Analysis and identification
using authentic standards was as detailed above for analysis of plant extracts.

Statistical analyses. The locally weighted scatterplot smoothing (LOWESS) function
was employed to generate a polynomial regression trend line for each of the kinetics plots
(95). Similar results were obtained using the R PK package (96), which was used to
compute the area under the serum concentration versus time curve (AUC). Specifically,
functions relevant to the serial sampling design employed in this study were applied.
Based on mean concentrations at the various time points, the method of residuals was
used to estimate a first order elimination rate constant (and half-life) as well as a first
order absorption rate constant.

Ethics Statement. This study was conducted in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Massachusetts (Protocol# 2011-0015).
All efforts were made to minimize suffering of animals during experimental procedures.
Theory
Oral consumption of dried leaves of A. annua is showing therapeutic promise (41, 89,
90). In contrast to what is known for pure artemisinin, little is known about how the drug
moves from orally ingested plant leaves (e.g. pACT) into the blood stream. Comparing
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the pharmacokinetics of the plant-delivered drug and one of its most common metabolic
products in the serum of healthy and infected animals will improve our understanding of
artemisinin metabolism and help clarify how such a therapeutic could eventually be
implemented.

Results and Discussion
Similar to a preliminary study that compared oral gavage of either pure artemisinin or
dried A. annua leaves (pACT) in healthy mice (49), we fed pACT to healthy or P.
chabaudi-infected mice and measured artemisinin and deoxyartemisinin in the serum for
two hours post gavage (Fig. II.2). The same data are replotted in Fig. II.3 to depict the
independent kinetics of artemisinin and deoxyartemisinin in healthy vs. infected mice.
The first order elimination rate constant for artemisinin in pACT-treated healthy mice
was estimated to be 0.80 hr-1, which corresponds to an elimination half-life (T½) of 51.6
min as determined by the method of residuals (45 ± 5.75 via the PK package of Jaki and
Wolfsegger, 2011), similar to that observed in rats by Niu et al. (1985)(97). The first
order absorption rate constant was estimated at 1.39 hr-1. Cmax and Tmax were 4.33 mg L-1
and 60 min, respectively (Table II.1). The area under the curve (AUC) for the length of
this study was 299.5 µg·min mL-1. In contrast, the AUC for pACT-treated infected mice
was significantly greater at 435.6 mg·min L-1 (Table II.1).
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Fig. II.2. Pharmacokinetics of artemisinin and one of it metabolites, deoxyartemisinin in
serum of healthy (right) and P. chabaudi-infected (left) mice. Mice (n = 4 - 6 per time
point per treatment group) were orally gavaged with dried leaves of A. annua to deliver
100 mg kg-1 body weight dose of artemisinin; bars show SE and * p < 0.05, *** p <
0.001 via Student’s t- test.

Fig. II.3: Pharmacokinetics of artemisinin (left) and one of it metabolites,
deoxyartemisinin (right) in serum of healthy and P. chabaudi-infected mice. Mice (n = 4
- 6 per time point per treatment group) were orally gavaged with dried leaves of A. annua
to deliver 100 mg kg-1 body weight dose of artemisinin; bars show SE and * p < 0.05,
*** p < 0.001 via Student’s t- test.
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Serum levels of artemisinin in the infected mice continued to rise over the 120
min of the study period (Fig. II.2), and as a result, the T½ was not determined; Cmax and
Tmax were estimated at ≥ 6.64 mg L-1 and ≥ 120 min, respectively. The key
pharmacokinetic descriptors are shown in Table II.1 and are consistent with those of an
earlier preliminary study using only healthy mice (49) and with other studies (97, 98)
using rats fed pure artemisinin.

Artemisinin
Dose per animal

Disease

(mg AN kg-1)

status

# of subj.

C max

T max

T½

AUC

(mg L-1)

(min)

(min)

(mg·min L-1)

100

healthy

4-6

4.33 ± 0.40

60

51.6

299.5a

100

infected

5

≥ 6.64

≥ 120

nd

435.6b

Table II.1. Pharmacokinetic parameters for artemisinin after oral gavage of healthy or P.
chabaudi-infected mice with pACT. Animals were fed A. annua dried leaves (pACT) to
deliver 100 mg AN kg-1; average body weight was 23 g; nd, not determined. Letters a,b
after AUC values indicate statistical difference at p ≤ 0.05; values are ± SE.
Batty et al. (2008) compared the pharmacokinetics of dihydroartemisinic acid
(DHA) in healthy and Plasmodium-infected mice that were administered a single
intraperitoneal dose of DHA (100 mg kg-1) and found no significant difference in
elimination half-lives. Since we was unable to determine T½ for infected mice in our
experiment, we cannot compare it to healthy mice(99). Although a direct comparison
cannot be made between the pharmacokinetics of DHA and artemisinin, in contrast to
Batty et al (2008), healthy mice in our study had a significantly lower AUC than infected
mice.
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Because it is one of several liver metabolic products of artemisinin, we also
measured deoxyartemisinin (66). Like many other drugs, artemisinin is metabolized in
the liver by cytochrome P450s including CYP2B6 and CYP3A4 (66), yielding a number
of compounds including deoxyartemisinin, deoxydihydroartemisinin, 9,10dihydrodeoxyartemisinin, and a metabolite named crystal 7 that are found in human urine
(100). Each of these degradation products lacks the endoperoxide moiety present in
artemisinin, and is therefore therapeutically inactive (100). In contrast to its metabolism
in healthy mice (Fig. II.2), metabolism of artemisinin to deoxyartemisinin appeared to be
suppressed in the infected mice (Fig. II.2); infection retarded the capacity of the mice to
form deoxyartemisinin from artemisinin over the two-hour study period. Overall,
artemisinin concentrations decreased with a concomitant rise in deoxyartemisinin levels,
but only in healthy subjects. In contrast, in infected mice artemisinin levels continued to
rise over the study period whilst deoxyartemisinin levels fell and then remained constant.
A. annua contains a diverse group of compounds (101) including flavonoids and
monoterpenes that have been shown to inhibit P. falciparum (57, 92-94); many also have
been shown to inhibit CYP3A4 (102-104).

Results showed an initial dip in artemisinin levels at 15 to 30 minutes in healthy
subjects, which we attributed at least partially to conversion of artemisinin to
deoxyartemisinin (Fig. II.2). The metabolism of artemisinin to deoxyartemisinin appeared
to be biphasic, declining slightly between 30 and 60 minutes, and then rising thereafter.
The rising arm of the artemisinin pharmacokinetic profile in healthy mice occurred
during this period of decreased metabolism to deoxyartemisinin; here, absorption
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exceeded elimination. When Du et al (2012) measured deoxyartemisinin in healthy rats
given a single oral dose of pure artemisinin (40 mg kg-1), the Tmax of deoxyartemisinin
was 30-60 min longer than that of artemisinin (60 min)(98). Their artemisinin
metabolism kinetics were the opposite of our results for a single oral dose of pACT
where the peak of artemisinin was later than the first peak for deoxyartemisinin, but
earlier than the second deoxyartemisinin peak (Fig. II.2). The pharmacokinetics in rats is
not necessarily the same as in mice, so this may account for the differential response
between our two sets of results.
We also examined the effects of mouse chow on pure artemisinin entry into the
serum. Mouse chow contains a variety of plant materials including soy, oats, wheat,
alfalfa, beet pulp, corn, etc. No artemisinin was detected in the serum of mice fed 100 mg
AN kg-1 body weight (Table II.2), a result consistent with the reported poor availability of
the pure drug (105). When plant material was present either as mouse chow or A. annua
pACT, the level of artemisinin in the serum rose to 2.44 and 4.32 mg L-1, respectively,
indicating that the presence of plant material, even that in mouse chow, had a positive
impact on the appearance of artemisinin in the blood (Table II.2). These results were
consistent with preliminary study (49). A. annua leaves can contain as much as 1.4%
(w/w) essential oils (101), which may enhance solubility and thus bioavailability of the
nonpolar artemisinin molecule.

For a human comparison, Giao et al. (2001) showed that when humans were
given 500 mg oral doses of pure artemisinin (twice on day 1, then once thereafter for
days 2-7), the level of recrudescence was 25%(106). In a summary of early human trials,
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oral delivery of at least 600 mg per patient for 5 days was required to achieve ≤ 10%
recrudescence (105). More recently a Kenyan clinical trial with four cohorts (4 x 12
subjects) of malaria patients (90) showed that patients receiving dried A. annua leaf
tablets containing 11.1 mg artemisinin (twice on day 1, so 22.1 mg d-1) followed by 7.4
mg artemisinin (twice a day for days 2-6, so 14.8 mg d-1) had 9.1% recrudescence (107).

Mouse treatment

Artemisinin (mg L-1)

Healthy untreated (3 pooled mice) a

0

Healthy + 100 mg AN kg-1 (3 pooled mice) a

0

Healthy + chow + 100 mg AN kg-1 (3 pooled mice) a 2.44
Healthy + pACT at 100 mg AN kg-1 (n = 5)

4.33 ± 0.40b

Infected + pACT at 100 mg AN kg-1 (n = 5)

3.78 ± 0.50b

Table II.2. Artemisinin in serum 60 min post pACT or pure artemisinin gavage.
a
These mice were treated in groups of three; blood was harvested and pooled prior to
extraction and measurement of artemisinin, so SE was not calculated.
b
Values are ± SE.
Furthermore, increasing the amount of dried leaf tablets did not improve therapeutic
response, suggesting that maximum effective dose had been achieved. Thus, although the
patients treated with dried leaf tablets received about 3-4% the equivalent amount of pure
artemisinin used in earlier studies (105, 106), they had an equal or better therapeutic
outcome than patients treated with pure artemisinin. Those results are consistent with the
results of this study.
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Conclusions
To our knowledge this is the first comparison between healthy and diseased animals of
the pharmacokinetics of artemisinin and one of its liver metabolites, deoxyartemisinin,
from orally delivered dried leaves of A. annua. When accompanied by plant material,
more artemisinin enters the blood stream, demonstrating a beneficial effect of the plant
matrix on the bioavailability of artemisinin. These results have implications for possible
therapeutic use of pACT in treating malaria and other artemisinin-susceptible diseases.
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Introduction
The fight against malaria predates the discovery of its causative agent. For
centuries malaria-associated fever was treated using herbal remedies. In the west, quinine
(Cinchona bark extract) was the only affordable treatment against malaria until Paul
Ehrlich’s magic bullet concept was adopted and thousands of synthetic compounds were
tested against malaria parasites. Very few of these compounds were effective and safe for
human use, but in the 1930’s chloroquine rose to ascendancy as a miracle cure for
malaria (108). In the late 1950s, chloroquine was the main weapon when the World
Health Organization launched the Global Malaria Eradication Program (GMEP).
Development of drug resistant parasites and concomitant failure of chloroquine as the
drug of choice lead to the eventual demise of GMEP by the close of the 1960s. Following
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chloroquine’s failure, various antimalarial compounds were serially deployed one after
another, and each unfortunately faced the same demise leaving millions of malaria
patients without affordable treatment.
In 1970s artemisinin was discovered as a pure drug extract from Artemisia annua.
In wide scale clinical trials, artemisinin showed poor pharmacokinetic properties but
nonetheless demonstrated potent antimalarial activity with a high safety profile (109). It
was determined that AN was best when used in combination with other antimalarial
drugs, mainly mefloquine, which became known as Artemisinin Combination Therapy
(ACT) (110). It was hoped that use of ACTs would minimize risk of drug resistance.
However, in 2005 evidence arose of P. falciparum resistant to ACTs in South East Asia
(30-34, 111). The fight against malaria again entered another critical phase trying to
avoid ACT from following chloroquine’s path towards obsolescence with no affordable
replacement in sight.
WHO has cautioned against use of non-pharmaceutical sources of artemisinin
because of the risk of delivering sub-therapeutic doses that could exacerbate the
resistance problem (112). This warning is valid given the low artemisinin content of most
extractions and tea/infusions utilized for most non-pharmaceutical plant based therapies.
However, in 2012 we demonstrated the efficacy of the whole plant—not tea, not
infusion—as a malaria therapy and found it to be more effective than a comparable dose
of pure artemisinin in a rodent malaria model (41). We contend that Whole Plant (WP)
A. annua therapy could provide a more abundant and affordable source of artemsininbased therapy by eliminating need for artemisinin extraction during manufacture.
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WP is more effective than monotherapeutic artemisinin because WP constitutes a
naturally occurring combination therapy that augments artemisinin delivery and
synergizes its activity. This plant Artemisinin Combination Therapy (pACT) is the result
of evolutionary refinement of the plant’s secondary metabolic products into a resilient
and multi-component defense system. As has been demonstrated for other combination
therapies, we hypothesize that WP-based pACT will: (1) overcome existing resistance to
monotherapeutic pharmaceutical artemisinin, and (2) increase the longevity of this
therapy by delaying the onset of parasite resistance among wild types. Here we’ve tested
these two hypotheses in two mouse malaria models, artemisinin-resistant Plasmodium
yoelii (ART) and artemisinin-sensitive Plasmodium chabudi chabaudi (ASS).

Materials and methods
Rodent Malaria Parasites: All experiments were performed using an appropriate rodent
malaria model, obtained through the Malaria Research and Reference Reagent Resource
Center (MR4) as a part of the BEI Resources Repository, NIAID, NIH. For long-term
selection experiments, we chose P. chabaudi (ASS; MRA-429) because of its known
susceptibility to WP and artemisinin treatment. P. yoelii (ART; MRA-421) was chosen as
available an artemisinin-resistant strain (ART).
Plasmodium chabaudi (ASS): Tubes of blood collected from infected mice, were
removed from liquid nitrogen storage and left at room temperature for 30 minutes. To
activate parasite stocks, two C57BL/6 mice were injected intraperitoneally (i.p.) with 200
µL of infected blood. Percent parasitemia was determined in Giemsa-stained thin blood
smears days 3-7 post-infection (p.i.). Seven days after inoculation, one mouse was
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euthanized and cardiac puncture was used to collect blood into lithium heparin tubes.
Infected blood was volumetrically adjusted by dilution in DPBS to create a 200 µL
aliquot of 105 infected erythrocytes for infection into two additional mice for a second
round of activation. The activated parasites were used in subsequent drug selection and
resilience tests.
Plasmodium yoelii (ART): To revive parasites after long-term storage in liquid nitrogen,
two C57BL/6 mice were injected (i.p.) with 200 µL of infected blood. Seven days after
infection to build up parasitemia, one mouse was euthanized and cardiac puncture was
used to collect blood into lithium heparin tubes. Infected blood was volumetrically
adjusted by dilution in DPBS to create a 200 µL aliquot of 107 infected erythrocytes for
infection into four additional mice. Two mice were immediately treated with a dose of
150 mg/kg AN recommended by the provider to activate and maintain resistant
phenotype, while the other two mice were left untreated as controls. Seven days post
inoculation, infected blood of one mouse, which first reaches 2% parasitemia from each
group, was used in the next passage. Activation for AN resistant phenotype was repeated
over 10 passages until the treated and untreated mice reached 2% parasitemia at the same
time. The activated parasites were used in the subsequent challenge.
Anti-malarial treatments. Artemisia annua L. (SAM cultivar; voucher MASS
00317314) containing 1.48±0.06% AN (dry weight) was used in this study. Detailed
information about plant material and AN analysis was reported in our previous work (41,
83). To test dose dependent effects, we used two doses of each treatment such that the
amount of artemisinin was equivalent in the two low (WPLO and ANLO) and the two high
(WPHI and ANHI) treatment groups.
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Mouse feeding and drug delivery details: Each mouse in the WPLO and WPHI groups
received 40 mg and 200 mg of dried A. annua plant powder corresponding to 24 mg
AN/kg and 120mg AN/kg live body weight respectively. Plant powder was mixed with
water to a final volume of 0.5 mL (WPLO) and 0.75 mL (WPHI). Each mouse in the
artemisinin ANLO and ANHI groups received 600 µg or 3000 µg of AN (Sigma-Aldrich
Chemical, St. Louis, MO) corresponding to 24 mg AN/kg and 120mg AN/kg,
respectively, which was freshly dissolved in 60 µL of DMSO mixed with water and
40mg or 200mg of powdered sieved mouse chow to a final volume of 0.5 or 0.75 mL,
respectively. Placebo control (CON) consisted of 60 µL DMSO, mixed with water and 40
mg powdered sieved mouse chow to a final volume of 0.5 mL. Delivery of the
appropriate treatment/control was performed immediately after dose preparation by oralgastric gavage into each mouse using a feeding needle (18G, curved, 2”, and 2.25 pall
diameter). Individual mice were identified by tail markings using permanent marker.
Percent parasitemia was determined in Giemsa-stained thin blood smears from a drop of
peripheral blood obtained from the tail. Mice were observed twice daily for signs of
disease or stress.
Artemisinin resistant P. yoelii single dose response: An aliquot of 106 Plasmodium
yoelii (ART) infected erythrocytes was inoculated i.p. into each of 30 C57BL6, 12 week
old male mice weighing an average of 25 g, and were randomly divided into five groups
(WPHI and ANHI, WPLO, ANLO, and CON) of six mice per group. Food and water were
provided ad libitum for the first four days. On day four, food was withheld for 24 hours,
but water was freely available. Mice were treated on day 5-post inoculation. Percent
parasitemia was determined every 24 hours in Giemsa-stained thin blood smears for the
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first four days post inoculation, then every eight hours for 48 hours post gavage, and
again on 24 hour intervals for days 8-13 p.i. All mice were euthanized on day 13 p.i. via
asphyxiation in a CO2 chamber followed by cervical dislocation.
Artemisinin resistant P. yoelii curative treatment: An aliquot of 107 Plasmodium
yoelii (ART) infected erythrocytes was inoculated i.p. into each of 12 DBA/2, 12 week
old male mice, which were randomly divided into two groups (WPHI, ANHI ) of six mice
per group. Starting on day 2 post-inoculation, each mouse in the WPHI and ANHI groups
received 9 daily dosing of 200 mg plant material (corresponding to 120mg AN/kg) and
3000 µg AN (corresponding to 120mg AN/kg) respectively. Percent of parasitemia was
determined every 24 hours in Giemsa-stained thin blood smears from days 1-24 p.i., then
every 72 hours for days 27-42 p.i. All mice were euthanized on day 42 p.i. via
asphyxiation in a CO2 chamber followed by cervical dislocation.
Selection for drug resistance and resilience test: Parasites were selected for resistance
following the 2% relapse technique (113-115), in which a single treatment dose is given
immediately after parasite inoculation to each mouse in the treated group, while a control
group is inoculated and left untreated. The delay in reaching a 2% parasitemia in the
treated group compared to the time required to reach the same parasitemia in the control
group is the 2% delay time (113, 115). In each selection passage three groups of two mice
were inoculated i.p. with 107 red blood cells infected with AN-sensitive Plasmodium
chabaudi chabaudi (ASS). Mice used in selection for AN resistance received single dose
of 2500 µg of AN corresponding to100mg/kg, on the other hand mice used in selection
for WP resistance received 167 mg of WP material corresponding to100mg/kg AN in
WP, while mice use as control received placebo. Gavaged materials were prepared as
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previously mentioned. Inoculations to the next passage occur on day 7 when all groups
passed 2% parasitemia and build up enough parasitemia for the next passage. Seven days
post inoculation, blood of one mouse, which first reaches 2% parasitemia from each
group, was used in the following passage. On passage number 17 AN dose was doubled
in the AN group after three consistent passages of zero delay time (AN treated group
reachs 2% parasitemia at the same time as the control group). Parasites were considered
resistant to a given dose if no delay time for three consequent passages. Selection for
WP resistance ended on passage number 48.
Statistical analysis. We fit linear mixed models to estimate and compare the average
parasitemia for each treatment group at each measured time point. Including a random
intercept for individual mice allowed us to adjust for repeated observations on the same
mouse. Single dose analysis compared the CON, WPLO, WPHI, ANLO, and ANHI
treatment groups at all measured time points.
For each model, 10,000 Markov chain Monte Carlo (MCMC) samples were
drawn from the posterior distributions of the average parasitemia levels for each
treatment group at each time point. Then, 95% confidence interval endpoints for a
particular parasitemia level were established at the 2.5th and 97.5th quantiles of the
MCMC samples for that parameter. An estimated difference between two groups was
declared “significant” if the 95% confidence interval for the difference did not cover
zero. Analyses were conducted using the statistical software R v2.15(62) and the lme4
package(63), fig. III.1 was produced using the ggplot2 package.
Ethics Statement. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
	
  

51	
  

	
  
National Institutes of Health. All efforts were made to minimize suffering of animals
during experimental procedures.

Results and Discussion
Previously, we found that dried whole plant A. annua kills P. chabaudi malaria
parasites more effectively than a comparable dose of pure pharmaceutical artemisinin
(AN). Here, we show that dried whole plant A. annua effectively kills malaria parasites
resistant to artemisinin. Mice treated with single dose of WPHI (corresponding to 120
mg/kg AN) showed significantly greater reduction in parasitemia than those treated with
a single comparable dose of ANHI (120mg/kg) from 16 to 168 hours post-treatment (Fig.
III.1). Mice treated with ANLO did not differ in parasitemia from those administered a
placebo at any time point. Treatment with WPLO (corresponding to 24 mg/kg AN) was as
effective as ANHI, despite the fact that ANHI dose contains 5 times more AN/kg (Fig.
III.1). In these single dose studies, all parasite populations recrudesced around day 5 posttreatment, which is typical of this parasite model.
To test whether WP can completely clear infection, we administered multiple
dose daily treatment of WPHI corresponding to 120 mg AN/Kg/day for 9 consecutive
days. Multi-dose treatment reduced P. yoelii ART parasitemia below 2% for seven days
post inoculation and to less than 1% from day 8 until complete clearance of parasitemia
on day 14-post inoculation. Mice treated from both WP treatment groups were normal
and did not show any signs of sickness. Infected groups of mice treated with comparable
multiple doses of pharmaceutical AN (120mg AN/kg/day) for 9 days had mean
parasitemia of 6% through day 7 with complete clearance on day 18-post inoculation
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(Fig. III.2). Cured mice in WP and AN groups were monitored by Giemsa stained thin
blood smears taken every 72 hours from day 24 until mice were euthanized on day 42 and
no recrudescence was observed.

	
  

Fig. III.1. AN-resistant P. yoelii (ART) single dose comparisons of WP and AN
treatments: WPLO (N=6) and WPHI (N=6) received in planta artemisinin at 24 mg/kg and
120 mg/kg, respectively; ANLO (N=6) and ANHI (N=6) received pure artemisinin at 24
mg/kg and 120 mg/kg, respectively. Placebo control (CON, N=5) received only mouse
chow. Dark lines indicate average parasitemia by treatment type. Lighter lines show
individual mouse trajectories. Shaded regions indicate the 95% confidence interval for
the means calculated based on normality assumptions. Arrow indicates time of treatment
Having demonstrated that WP is effective against artemisinin-resistant parasites,
we conducted an artificial evolution experiment to compare rates at which resistance to
these two modalities arose among wild-type parasite lines. Using the 2%-relapse
technique for long-term selection of drug resistance in Plasmodium chabaudi parasites,
we achieved stable resistance to 100mg/kg AN at passages 13-16. On passage number 17,
the dose was increased to 200mg/kg AN. Parasites acquired tolerance to this double dose
after 40 passages with constant delay time less than 25% of the first passage (Fig. III.3).
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Fig. III.2: AN-resistant P. yoelii (ART) curative treatment: Mice were infected with P.
yoelii (ART) and treated with either pure artemisinin (N=6) at 120 mg/kg, or WP in
planta artemisinin (N=6) at 120 mg/kg. Mice were treated for 9 consecutive days
starting on day 2 post-infection. ** = P < 0.01. Error bars represent SD.

The comparable dose of WP (100mg/kg AN) was more resilient such that
resistance was achieved after only 45 passages. The WP treatment of 100mg/kg was
even more resilient than the doubled dose (200mg/kg) of pure AN in the second phase of
selection. P. chabaudi generally develops resistance to antimalarial drugs faster than
other rodent malaria species (113). In a similar selection study using a combination
therapy of artesunate 30mg/kg/day + mefloquine 5mg/kg/day- given over three days,
resistance was achieved after 27 passages (116). Just as ACT treatment is more resilient
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than a purified AN (117), we contend that WP treatment is more resilient than a
pharmaceutical AN because WP treatment contains multiple and complementary
compounds effective in killing malaria parasites including those resistant to
pharmaceutical AN.
A. annua extracts have a number of different practical uses in agriculture and
public health. These include repellency against stored product beetles (118), larvicidal
activity against Anopheles stephensi (119), insecticidal activity against elm leaf beetle
(120), and use as an acaricide (121). Moreover, AN and its derivatives have also shown
to have effects on a number of viruses replication, a variety of human cancer cell lines
(35, 36), several neglected tropical parasitic diseases including schistosomiasis (44),
leishmaniasis (45, 46), New- and Old-World trypanosomiases (47), and many livestock
diseases (48).
To better understand the reasons for efficacy of phytochemicals in killing
mammalian parasites, we must consider carefully plant biology and evolution. Like all
plants, A. annua lacks an immune system that can adapt somatically to its natural enemies
including viruses, bacteria, fungus, parasites, insects and other animals. Instead of an
acquired adaptive immune response, plants possess a complex repertoire of chemical
defenses against a wide range of organisms. Evolutionarily successful plant species such
as A. annua possess large arrays of bioactive compounds providing resilient protection
against micro and macro threats (122) (123). The bioactive secondary metabolites of A.
annua are synthesized and stored in glandular trichomes, which are small cusps of
epidermal origin consisting of differentiated basal, stalk, and apical cells. Trichomes are
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specialized to synthesize, store, and secrete large amounts of phytochemicals including
artemisinin, flavonoids, phenolics and terpenoids (123-125).

Fig. III.3. Evolution of resistance in P. chabaudi (ASS) exposed initial
dose of 100 mg/kg AN (upper blue line), then increased (Arrow) to 200
mg/kg AN (upper red line) and WP 100 mg/kg in planta artemisinin (
lower blue line) , following the 2% relapse technique.

Components of the A. annua chemical defense include allelopathic factors that
inhibit neighboring plants from germinating or growing. Artemisinin is known to have
potent herbicidal activity acting on the electron transport in chloroplast membrane (124)
	
  

56	
  

	
  
and plant cell membrane (39, 126). That these defenses are also effective at killing a
mammalian blood-borne parasite seems at first coincidental, however there is a plausible
evolutionary explanation for this cross species protection. Malaria parasite cells contain
apicoplasts, which were derived initially from the same ancestral cyanobacterial
endosymbiont that gave rise to chloroplasts in plants (127). This vestigial organelle in
Plasmodium is believed to be an essential target of the A. annua allelopathy defense
mechanisms (38).
It is well known that the bacterial origin of apicoplasts renders malaria parasites
susceptible to antibiotics, such as doxycycline, which have known to inhibit transcription
and translation of prokaryotes by blocking its replication and malaria parasite cell death
(127, 128). Likewise, the presence of plant-like organelles and pathways in parasites that
are absent in the human host present intriguing prospects for co-opting herbicidal
compounds as medicaments(129). Various plant extracted herbicides already have been
found to have specific parasite killing activity against apicomplexan parasites including
P. falciparum, Cryptosporidium parvum and Toxoplasma gondii (38). These herbicides
may be synthetic or, as with the WP therapy discussed here, derived from naturally
occurring plant forms.
Among the phytochemical repertoire that is synthesized and located in the
trichome are the terpenoids, the essential oil constituents of A. annua giving the plant its
fragrance (101). Terpenoids are compositions of component isoperenes with extensive
branching and cyclization ability. Plasmodium spp. possesses its own terpenoid pathways
present with the apicoplast which is essential for the growth and replication of intra and
extra erythrocytic stages (130) (128). Due to similarity among the intermediates of plant
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and parasite pathways, some of the plant derived terpenoids have been shown to disrupt
function of the apicoplast leading to parasite killing (131). Among the anti-parasitic
terpenoids is nerolidol that inhibits the biosynthesis of the isoprenic chain (132) and
limonene that inhibits the protein isopenylation in the erythrocytic stages of P.
falciparum (133). Nerolidol, linalool, limonene and farnesol have IC50 against P.
falciparum of 760 nM, 0.28mM, 1.22mM and 64uM, respectively (134). Monterpenes
isolated from eucalyptus oil (80% cineole) inhibit chloroquine-resistant and chloroquinesensitive P. falciparum by mechanisms believe to be connected to membrane disruption
(135). Indirect evidence of other non-AN antimalarial activity in A. annua is provided the
documented parasite killing using related species of Artemisia that do not produce
artemisinin (67). Moreover, several other sesquiterpenes in A. annua have shown activity
against malaria parasites (67). The ability of plants to produce a virtually unlimited
diversity of terpenoids by elongations, cyclizations, and rearrangements gives potential
for redundant and resilient anti-parasite killing activity (11, 136)
As in the challenge experiments against malaria parasites, the allelopathic activity
is higher for the whole plant than a comparable dose of its pure extract AN when
incorporated into soil (137). The higher allelopathic activity of whole plant A. annua than
its pure extract AN is attributable to the synergism among A. annua constituents (137)
and/or the presence of other constituents of A. annua that have potent herbicidal activity
(37). This same synergism between A. annua constituents has been reported to potentiate
the antimalarial activity against P. falciparum (14, 41, 48, 67).
The fact that antimalarial activity of WP is better than artemisinin can possibly be
explained by enhanced bioavailability of artemisinin due to inhibitory effects of some A.
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annua flavonoids on the hepatic and intestinal cytochrome P450 enzymes that metabolize
artemisinin (66, 83). Plant material seemed to enhance by >40 fold the amount of
artemisinin that entered the blood stream (49). The presence of plant material in mouse
chow significantly increased the amount of artemisinin that appeared in the serum (83).
Whole plant A. annua may also have increased activity against malaria parasites
due to the synergism among some key flavonoids and artemisinin (14, 41, 48, 67) or by
the antimalarial activity of other A. annua constituents independent from AN. Certain A.
annua flavonoids (artemetin, casticin, chrysosplenetin, chrysosplenol-D, cirsilineol, and
eupatorin) showed antimalarial activity against P. falciparum in the absence of AN (138).
Similarly, four dietary flavonoids—kaempferol, quercetin, apigenin and luteolin—that
are present in A. annua (101) were tested against chloroquine-sensitive P. falciparum
(strain 3D7) and showed 50% Inhibitory Concentrations (IC50 ) of 33uM, 15uM, 20uM
and 11uM, respectively. Also, these four flavonoids were effective against chloroquineresistant P. falciparum (strain 7G8) giving IC50 of 25uM, 14uM, 13uM and 12uM,
respectively. Similarity of IC50 values for each of these four flavonoids regardless of their
chloroquine sensitivity suggests that the flavonoids are acting on targets distinct from
those of chloroquine.
The likelihood of developing resistance is greater for a single antimalarial
compound than a combination therapy. Increased resilience of WP relative to a
comparable dose of pharmaceutical AN is consistent with this pattern. Resilience of WP
can be explained by the presence of a large phytochemical repertoire of small molecules
that target many active enzymatic sites essential for malaria parasite survival and growth,
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making it more difficult for parasites to accumulate necessary resistance mutations in the
ensemble of genes responsible for encoding those essential target sites.
The 19th century conceptualization of “magic bullets” led us to the serial use of
monotherapies that blindly select for resistant micro- and macro-organisms throughout
the 20th century. The benefits realized in roughly the first half of that period in medicine
and agriculture were undone in the latter half by proliferation of resistance to antibiotics,
antimalarials, insecticides and herbicides. A renewed appreciation for evolution and the
adaptive potential of the targeted organisms has lead to more sustainable approaches
using combinations of control agents. The success of the combinatorial approach is
evidenced throughout nature, and A. annua is a prime example with its repertoire of
several hundred compounds comprising that plant’s defense system. If plants had
followed the pharmaceutical model of serial production of single component protection
against its enemy, they would gone extinct long ago (14). The WP anti-malarial therapy
serves as a case study of how those resilient naturally occurring systems might be coopted for human use. While much work remains, the clear evidence of the efficacy of WP
as a naturally occurring combination therapy pACT warrants its further consideration to
explore how we might develop inexpensive, abundant and resilient malaria therapies
from a non-pharmaceutical product.
Conclusions
Emergence of artemisinin-resistant malaria parasites raises urgent need for
alternative treatment that is affordable, resilient and effective against resistant parasites.
In our previous study we reported that antimalarial activity of whole plant Artemisia
annua was at least 5 times more effective than an equivalent dose of its pure extract AN
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(41). Here we also show that dried whole plant material of A. annu is more effective in
killing malaria parasites resistant to AN. We’ve also shown that WP is more resilient
than pharmaceutical AN and may actually delay the onset of resistance. While the exact
mechanisms still need to be identified, the antimalarial activity of WP against
artemisinin-resistant parasites can be explained by increased bioavailability of AN,
synergism among AN and some A. annua constituents and/or the presence of other
compounds in A. annua that may have antimalarial activity independent from AN. The
efficacy and resilience of A. annua-based WP treatment against rodent malaria provides
compelling reasons to further evaluate the role of non-pharmaceutical forms of AN to
treat human malaria.
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Introduction:
Babesiosis is a tick-borne disease caused by haemotropic apicomplexan protozoa of
the genus Babesia, which are transmitted mostly by Ixodes ticks but also by blood
transfusion and prenatally(28, 139-143). After trypanosomes, Babesia is the most
common mammalian blood parasite (140). Like Plasmodium, Babesia invades
erythrocytes, has an invertebrate vector, and the symptoms of the two diseases are
similar, including fever, flu-like symptoms, chills, headache, anemia, hemoglobinuria,
and myalgia. In regions where malaria is endemic, co-infection with Babesia parasites
has been observed, and babesiosis may be misdiagnosed as malaria (27).
The life cycle of Babesia requires a tick vector for sexual reproduction and
transmission to the vertebrate host. After gametogenesis in the tick midgut, the motile
embryo replicates in ovaries and salivary glands. Sporozoites in the salivary glands are
transmitted to vertebrate hosts parasitized by ticks, while ookinetes in ovarian cells are
transmitted to the tick's offspring (28). Unlike Plasmodium and Theileria, babesial
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sporozoites directly invade erythrocytes without the need for replication in hepatocytes
(Plasmodium) or lymphocytes (Theileria).
To date, seven species of Babesia have been found to cause human babesiosis:
Babesia microti, B. divergens, B. bovis, B. canis, B. duncani, B. venatorum and Babesia
KO1 (28). Babesia has been diagnosed in increasing numbers of humans in recent years
due to greater medical awareness and increased numbers of immunocompromised
patients (28). Because Babesia has historically been a disease of domestic animals,
current antibabesial pharmaceuticals may be licensed only for veterinary, but not human
use (28). The lack of routine treatment for Babesia and the similarity between Babesia
and Plasmodium triggered drug development investigators to test antimalarial drugs
against different species of Babesia (144). The combination of quinine and clindamycin
was effective in treating human and animal cases. However B. microti infections
persisted after treatment and adverse reactions to treatment were reported in about 25%
of all treated cases (145) (146, 147). Immunocompromised patients are usually treated
with a combination of atovaquone and azithromycin, but relapses after prolonged
treatment suggested that B. microti readily evolved resistance to these compounds (148).
Resistance against atovaquone, another common antimalarial, was reported in hamster B.
microti (149). The lack of effective treatment for human babesiosis, particularly in
immunocompromised patients, creates an urgent need for new antibabesial therapeutics.
The difficulty of distinguishing malarial and babesial infections and the frequent coinfections with the two diseases create the need for cost-effective treatments that combat
both diseases.
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Artemisinin, extracted from the herb Artemisia annua, is currently the preferred
treatment against malaria. To delay the onset of drug resistance, the World Health
Organization (WHO) recommended using artemisinin or its derivative, artesunate, in
combination with other antimalarial drugs, lumefantrine or mefloquine, in a treatment
known as Artemisinin Combination Therapy (ACT)(42). Beside antimalarial activity,
artemisinin and its derivatives have also shown efficacy against a number of viruses,
human cancers (35, 36), schistosomiasis (44), leishmaniasis (45, 46), trypanosomiases
(47) and possibly babesiosis (150).
At concentrations ≥ 2.6 µM, Goo et al. (2010) showed that, artesunate inhibited the in
vitro growth of B. bovis the causative agent of bovine babesiosis, but to inhibit B. gibsoni
the causative agent canine babesiosis, the concentration had to be raised 100-fold to 260
µM (150). In contrast in mice infected with B. microti, an intramuscular treatment of 50
mg kg-1 artesunate delayed, but did not completely quell parasitemia.
Recently, using a rodent malaria model P. chabaudi, we showed that oral
consumption of powdered dried leaves of A. annua (100 mg artemisinin kg-1 body
weight) inhibited parasitemia at least five-fold more than pure artemisinin (41). Plant
material seemed to enhance by >40 fold the amount of artemisinin that entered the blood
stream (49). There are many other compounds in the plant that may account for the
enhanced efficacy of orally consumed dried A. annua leaves and thus, we have called this
treatment plant Artemisinin Combination Therapy, pACT. Such a therapy would also be
more cost effective than current ACTs saving the cost of artemisinin isolation and
purification. Beside malaria, pACT represents a candidate treatment against many other
diseases susceptible to artemisinin and its derivatives.
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In light of the earlier study by Goo et al. (2010) and the potent activity of pACT
against malaria (150), we hypothesized that pACT may also have enhanced activity
against B. microti, the cause of most of human cases in the United States. The objective
of this work was to compare the therapeutic effects of pACT to those of the pure
compounds, artemisinin and artesunate, in a murine model of B. microti infection. We
hypothesized that the increased bioavailability of artemisinin from the whole-plant
material, combined with the possible additive and synergistic effects of other plant
compounds, could make whole-plant therapy more effective against babesiosis than
treatment with individual compounds.

Materials and Methods:
Treatments: Artemisia annua L. (SAM cultivar; voucher MASS 00317314) containing
1.48±0.06% artemisinin, 0.37% flavonoids, monoterpenes (e.g., 0.21% (w/w) camphor,
0.007% eucalyptol, 0.037% α-pinene) as determined by GC-MS was used in this study.
Plants were grown, harvested, dried, and leaves sieved and pulverized as previously
described (41). Artemisinin (AN) and artesunate (ART) were purchased from Sigma
Aldrich.
Parasite information: Cryopreserved isolates of Babesia microti were kindly provided
by Samuel Telford (Tufts University). To revive the parasites, cells were intraperitoneally
injected into two inbred male DBA/2 mice. The revived parasites were used in
subsequent experiments.
Mouse infection and feeding details: To test the effects of artemisinin intake on
parasitemia, inbred male DBA/2 mice 12 weeks old were intraperitoneally injected with
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107 infected red blood cells and randomly divided into four treatment groups: AN, ART,
pACT and CON (control) with eight mice in each group. Beginning two days after
parasite inoculation, mice were treated daily for six days via oral gastric gavage with
100mg/kg mixed with a water slurry of mouse chow containing either AN or ART and
water slurry of dried ground A. annua leaves (pACT) corresponding to 100mg AN /kg
body weight. Mice in the CON group were gavaged a placebo consisting of water slurry
of mouse chow only. Detailed information about mouse feeding, drug preparation and
parasitemia count can be found in Elfawal el al (2012)(41). Parasitemia was measured
daily on Giemsa-stained thin blood smears and mice were euthanized on day17 post
inoculation (Fig. IV.1).
Ethics Statement: This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Massachusetts (Protocol# 2011-0072).
All efforts were made to minimize suffering of animals during experimental procedures.

Results and discussion
We compared the antibabesial activity of a whole-plant (pACT) to that of pure
compounds used in conventional malaria treatment (AN and ART). Parasites were found
in blood of infected mice 48 hours after inoculation. Days 2-7 post-inoculation,
parasitemia increased, peaking on day 11; this was 4 days after cessation of treatments in
all groups. Parasitemia declined on days 12-14 post inoculation, then increased again on
day15 post inoculation (Fig. IV.1). Mice were euthanized 17 days post-inoculation when
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parasites were found in about 15% of erythrocytes. The course of infection was similar
to that previously observed in Babesia microti-infected mice (150, 151). None of the
treatment groups showed significant reduction in parasitemia in comparison to controls
treated with water slurry of mouse chow (Fig. IV.1).

Fig. IV.1: B. microti mean of daily parasitemia of four treatment groups: whole
plant A. annua corresponding to 100mg/kg (pACT), artemisinin 100mg/kg (AN),
artesunate 100mg/kg (ART) and placebo control (CON). Mice were treated once daily for
six days via oral gastric gavage starting two days post intraperitoneally infection with 107
parasite-infected red blood cells. Means of daily parasitemia were analyzed for statistical
significance by analysis of variance. P >0.05 was considered to be statistically not
significant.
The lack of effective antibabesial drugs and the similarity between Babesia and
Plasmodium in biology and disease symptoms have led to the testing of antimalarial
compounds against different species of Babesia (144). Chloroquine was the first
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antimalarial drug tested against human babesiosis without success (145, 152). Following
chloroquine many antimalarial compounds were tested and found to be ineffective
against Babesia microti including artesunate, mefloquine and halofantrine (144, 149,
153). In contrast, artesunate was found to be partially effective in controlling Babesia
microti and to delay the peak of parasitemia during treatment days, but it failed to
eradicate the disease or to control parasitemia levels that reached 19% and 24% only 5
days after the last treatment of 10mg/kg and 50mg/kg, respectively (150).
Artemisinin is a sesquiterpene lactone with a peroxide bridge that is responsible
for its antimalarial activity (154-156). The mode of action of artemisinin is under
considerable discussion with several proposed modes of action. One is interference with
digestion of hemoglobin by the parasite. Hemoglobin digestion yields toxic heme, but
the parasite forms crystalline polymers of insoluble nontoxic hemazoin in the digestive
vacuole. This mode of action, however, conflicts with reported activity of artemisinin
against younger stages of the malaria parasite and other parasites that lack hemazoin
synthesis and a digestive vacuole (157). A second possible mechanism for artemisinin
mode of action is through cleavage of its peroxide bridge by heme, producing a carboncentered free radical that alkylates, modifies and inhibits essential parasite molecules thus
resulting in parasite death (154-156). A third alternative proposes direct interaction
between artemisinin and the SERCA-like Ca+2 –PfATP6 calcium pump present in
Plasmodium; mutation in the PfATP6 gene is associated with artemisinin resistance (156,
158, 159). Iron-containing molecules are essential for enhancing artemisinin-PfATP6
binding and the heme-artemisinin complex interacts well with PfATP6 causing
modification in its molecular structure preventing calcium binding, leading to disruption
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of the SERCA-like pump (156). Iron containing molecules known to enhance
artemisinin activity by enhancing PfATP6 activity and other free radicals include heme
(154, 160-163), hemin (68, 162), denatured hemoglobin in the digestive vacuole (154)
and inorganic iron (164). When these four iron sources were tested for their ability to
activate artemisinin, heme was the best; inorganic iron was ineffective (154). In malaria
heme is produced de novo in the apicoplast, the plastid-like organelle exclusive to
apicomplexan parasites and involved in biosynthesis of heme, fatty acids, and isoprenoid
precursors. The antimalarial activity of artemisinin may be increased additively by the de
novo synthesized heme.
The intracellular parasite B. microti has a single membrane without a
parasitopherous vacuole. The importance of the second membrane and the
parasitopherous vacuole seems to be in host parasite interaction and forming the digestive
vacuole, the main target for many antimalarial drugs, where hemoglobin digestion takes
place. It has been suggested that in contrast to malaria, B. microti invades erythrocytes
using a mechanism other than membrane invagination (165). Although in Babesia the
double membrane is absent in mature trophozoites, it is present in the young merozoites
shortly after invasion thereby confirming that B. microti invades erythrocytes by
invagination like Plasmodium, but with rapid degradation of the second host membrane
shortly after penetration. A similar phenomena was observed in Eimeria manga (165).
Such a rapid degradation of the second membrane suggests a unique interaction with host
cells in obtaining nutrients and hemoglobin digestion (165, 166).
In further contrast to Plasmodium, B. microti has a highly polymorphic
intracellular stage with pseudopods forming host cytoplasm invaginations. Such
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invaginations were believed to be a digestive vacuole. However liberated parasites from
host cells were found to have vacuole-like structures lacking host cytoplasm (165, 166).
The absence of a digestive vacuole was confirmed using electronic microscope imaging
of different sections of the intracellular parasites showing invagination of the host
cytoplasm forming what is named pseud vacuole (165, 166).
The lack of a parasitopherous vacuole, a digestive vacuole, and hemazoin
formation in Babesia parasites has led to contrasting conclusions about the ability of
Babesia to digest hemoglobin. One opinion suggested that Babesia may completely
digest hemoglobin extracellularly without hemazoin formation and by unknown
mechanisms (167). On the other hand, it was also suggested that Babesia parasites may
not even digest hemoglobin (165, 166). The latter conclusion was recently supported by
sequencing the whole genome of B. microti and surprisingly, among all apicomplexan
parasites B. microti has only three nuclear chromosomes, its overall genome size is about
72% smaller than P. falciparum, and it lacks hemoglobin proteases (139).
In a molecular phylogenetic study using the full sequence of 316 genes, B. microti
was placed as paraphyletic group that was a root for all Babesiidae including both
Babesia and Theileria. Such a result confirmed the distinction between B. microti and
other piroplasms and suggested the need for creating a new genus for B. microti (139);
(168).
The increased surface area of the parasite with intra-erythrocytic polymorphic
shapes (pseudopods, whirls, and pseudo vacuole), the absence of the double membrane,
the absence of parasitopherous vacuole, the absence of hemoglobin proteases, and the
low metabolism of this parasite suggest that B. microti is highly dependent on the host
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red blood cell for obtaining nutrients by diffusion through its single membrane (165,
166). Dependence on host cells in obtaining essential amino acids is not a feature unique
to Babesia; P. falciparum also depends on host cells to obtain essential amino acids
unavailable from hemoglobin digestion (169). In contrast to apicoplast function in
Plasmodium that also synthesizes heme and fatty acids, apicoplast function in B. microti
is limited to synthesis of isoprenoid precursors and lacks heme biosynthesis (139). The
absence of the digestive vacuole and heme biosynthesis in Babesia may explain the lack
of activity of artemisinin or artesunate against B. microti. However, although Toxoplasma
gondi lacks hemazoin, digestive vacuole and hemoglobin digestion, it is still susceptible
to artemisinin. The anti-parasitic activity of artemisinin against T. gondi may be
explained by the de novo heme synthesized in its apicoplast. On the other hand,
artemisinin and its derivatives failed to control infection of Cryptosporidium parvum in
neonatal mice (170) and in in vitro culture (171). Among all apicomplexan parasites, only
C. parvum lacks the apicoplast. C. parvum also lacks the digestive vacuole and
hemoglobin digestion. The lack of artemisinin activity against C. parvum may be
explained by the lack of enough heme concentration either from hemoglobin digestion (as
in Plasmodium) or de novo synthesized (as in Plasmodium and Toxoplasma). Despite B.
microti harboring the apicoplast, that function is limited to isoprenoid synthesis, it lacks
both sources of heme. Thus, artemisinin and its derivatives failed to control infection in
B. microti similarly to C. parvum. In conclusion, the anti-parasitic activity of artemisinin
is dependent on enough heme concentration within the parasite.
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The antimalarial activity of pACT is better than artemisinin and is possibly
explained by enhanced bioavailability of artemisinin due to inhibitory effects of some A.
annua flavonoids on the hepatic and intestinal cytochrome P450 enzymes that metabolize
artemisinin (83). In contrast, enhanced generation of heme does not seem to occur in B.
microti, so greater bioavailability of artemisinin from pACT is moot.
Enhanced antimalarial activity of pACT is also potentially explained by the possible
synergism between artemisinin and one or more other constituents in A. annua including
terpenes, phenolic acids and flavonoids, (14, 48, 67, 172). For example, flavonoids were
shown to reduce the IC50 of artemisinin against P. falciparum (41, 57, 58). Although not
fully understood, methoxylated flavonoids enhanced formation of the artemisinin-heme
complex, which reportedly enhances artemisinin binding to SERCA-like calcium pump
and cleavage of the peroxide bridge releasing free radicals (68). The absence of antibabesial effects by Artemisia annua and its chemical components may reflect the
differences in artemisinin drug targets between Babesia and Plasmodium.

Conclusion:
Human babesiosis is an emerging disease caused by a parasite distinct from all
apicomplexans. The disease particularly affects immunocompromised people in
developing nations where malaria often co-infects and new treatments are urgently
needed. Although reported to be effective for other Babesia sp., and in contrast to
Plasmodium sp., none of the three forms of artemisinins tested here seem effective
against B. microti. The differential response of Babeisa sp. to artemisinins is likely the
result of significant differences in their cell biology and metabolism of hemoglobin. The
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apicoplast of both Plasmodium and Babesia has the nonmevalonate isoprenoid anabolic
pathway, which is susceptible to fosmidomycin, so this antibiotic could be used to treat
patients with malaria-Babesia co-infections. Although effective against malaria, some
Babesia species, and a number of other apicomplexans, neither pACT nor artemisinin and
artesunate are effective against B. microti, so the search for new therapeutics against this
debilitating disease must continue.
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FINAL CONCLUSIONS
Plant antimicrobial secondary metabolites are complex multicomponent matrices
with synergy among their components and biological activity against a broad spectrum of
microbes through a variety of mechanisms (13, 14, 173). During their own coevolution
with pathogens, animals evolved self-medication behavior relying on direct ingestion of
plant matrices of antimicrobial secondary metabolites which, when directly ingested,
could treat or prevent diseases. Plants have limitless ability to synthesize secondary
metabolites, which serve as plant defense against predation by microorganisms, insects,
and herbivores (174). Secondary metabolites give plants their odor, flavor and pigment.
Plants generate several categories of secondary metabolites: phenolics (simple phenolics,
quinones, flavonoids, tannins, coumarins), terpenoids, alkaloids and polypeptides (174).
The medicinal properties of plants come from the interactions of multiple constituents,
and its overall properties may never be completely achieved by using their component
parts (14). These interactions in medicinal plants are known as synergy, when the effect
of the combination is greater than the sum of the individual effects (14). Crude extracts
from many medicinal plants were found to be effective against viruses (175-179),
bacteria (180-185), protozoa (186, 187), helminths (188-190) and fungi (180, 182, 191).
Such antimicrobial properties are made of small molecules that fit into sites in enzymes
or receptors essential for pathogens survival. Because pathogens tend to develop
resistance, many of the plant’s secondary metabolites are developed to inhibit resistance
mechanisms (192).
About 25% of prescribed drugs and about half of newly discovered drugs are
from plant origin (193), and about 80% of the world population relay on plant-derived
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medicines (173, 194). But current pharmaceutical industry strives to isolate single active
compounds (195), and thus may overlook many useful complex secondary metabolites
with potential synergistic antimicrobial activity.
Use of single-target monotherapeutic drugs tends more often to select for microand macro-organisms resistance, whether that resistance is to antibiotics (196),
antiparasitic (110), insecticides (197), and herbicides (198). Prolonged use of
antimicrobial monotherapy leads to the evolution of drug resistance in microorganisms
that initially were sensitive but gradually adapt and develop resistance. Repeated use of
antimicrobial agent selects for resistant and select against sensitive microorganisms.
Microorganisms achieve drug resistance through number of mechanisms, including
reduction in drug uptake through efflux pumps, avoiding drug activity by drug
degradation or alteration, increased expression of drug target, decrease binding ability of
drug due to modification in its target (196, 199-201). Drug resistance can be innate to
microorganisms or acquired through mutation and horizontal gene transfer (196, 200).
Resistance-associated mutations are likely to be deleterious because they result in
metabolic pathway modification (200). The development of new mutation depends on
mutation rate and fitness cost, thus resistance-associated mutations are less favored or
costly in absence of the selective drug. If resistance phenotype requires two mutations,
the initial frequency of organisms harbor these two mutations is much lower than the
frequency of organisms harbor only one mutation. Thus the likelihood of developing drug
resistance to a combination therapy is much lower than developing resistance to
monotherapy (202). Similarly the likelihood of developing resistance to single compound
that require more than one mutation is much lower than those require single mutation.
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Combination therapy may delay the evolution of drug resistance more than monotherapy
(202), however if multiple compounds are actively target the same site, single mutation
may lead to resistance to combination of these compounds (110).
Herbal remedies have been used for several thousands of years, but resistance
does not seem to have appeared. In contrast isolated or synthetic compounds have
suffered from the appearance of resistant microorganisms. Matrices of secondary
metabolites are evolutionary designed to be effective against microorganisms using
hundreds of small molecules that target sites of multiple enzymes and receptors essential
for microorganisms (14). Such strategy of using synergic multicomponent defense system
enabled plants to thwart microorganism’s ability to develop resistance. Using complex
matrix of secondary metabolites by plants, microorganisms fall easy target for such
complexity, and to develop resistance against single component microorganisms will be
more vulnerable against others. Synergic activities of secondary metabolites were found
to enhance activity against resistant pathogens including bacteria (185, 203, 204) and
protozoa (14, 41, 48, 205).
Because it is almost impossible to generate hundreds of resistance-associated
mutations at once, against multiple repertoires of secondary metabolites, microorganisms
had to develop multidrug resistance involving protein pump located on cell membrane
throwing foreign molecules out of the cell. Facing similar matrixes of secondary
metabolites many microorganisms convergently develop MDR including bacteria (196),
protozoa (110), fungi (206), and viruses (207). In response to MDR, plants co-evolve
and produce secondary metabolites that are specialized to disrupt MDR. Phytochemicals
from many plant species were found to be effective against multidrug resistant pathogens.
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Crude leave extracts from Lantana camara L. were found to be effective against three
multidrug resistant Gram-positive bacteria: Methicillin-Resistant-Staphylococcus aureus
(MRSA), Streptococcus pyrogenes, and Vancomycin-Resistant-Enterococcus faecalis
(VRE); and five B-lactamase producing-Gram-negative bacteria: Acinetobacter
baumannii, Citrobacter freundii, Proteus mirabilis, Proteus vulgaris and Pseudomonas
aeruginosa. Dichloromethane extract had the most antibacterial activity against MRSA
with lowest Minimum Inhibitory Concentration (MIC), followed by methanol extract. On
the other hand the lowest antibacterial activity with highest MIC was observed in water
extract (208). Phytochemical analysis of dichloromethane extract approved the presence
of alkaloids, glycoside, terpenoids, saponins, flavonoids, tannins, and steroids. On the
other hand methanol extract lack tannins and glycosides. It was concluded that the more
secondary metabolites in extract the more antibacterial activity against bacteria (208).
Similarly extracts from Lygodium flexuosum L. were found to be effective against MDRMRSA and –VER (209). Alkaloids from Meconopsis simplicifolia were found to be
effective against MDR-K1CB1 P. falciparum (210). Extracts from Mangifera indica
leaves and bark were found to be effective against MDR-Dd2 P. falciparum (205).
Here we found dried whole plant (WP) Artemisia annua is at least five times more
effective than purified compounds in killing malarial parasites. Moreover WP overcomes
artemisinin-resistant malaria parasites. Moreover, whole plant A. annua was at least three
times more resilient against the evolution of drug resistance than purified artemisinin.
Enhanced pharmacokinetic and pharmacodynamic properties of whole plant A. annua
compared to purified artemisinin may be explained by the presence of a complex matrix
of secondary metabolites, some of which increases the bioavailability of artemisinin by
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inhibiting hepatic and intestinal enzymes that degrade artemisinin. This was supported
by our observation that plant material such as that found in mouse chow was critical to
the appearance of artemisinin in the blood of orally-treated mice. The pharmacokinetic
properties of artemisinin delivered in planta were also different between uninfected and
infected mice. Enhanced antimalarial activity of A. annua over artemisinin can be
explained by the presence of A. annua constituents with antimalarial activity independent
from artemisinin, including flavonoids and terpenes other than artemisinin. Alternatively,
non-artemisinin A. annua constituents with antimalarial activity may depend on the
synergistic effects of artemisinin to realize their parasite-killing potential.
Use of dried whole plant A. annua directly against malaria could dramatically
decrease the cost of therapy, giving hope to millions of people living in malaria endemic
regions. Because chemical synergism in the plant chemical matrix is common in
medicinal plants, we speculate that many whole plants material will show increased
bioactivity compared to compounds purified from them. Using plants in their whole form
will decrease drug production costs and eventually reduce healthcare costs.
Creating greater opportunity for use of whole plant therapy to fight human
diseases, no less than three fundamental paradigm shifts must occur in how the
pharmaceutical enterprise approaches use of whole plants in drug development.
The first shift must be to alter the objective for using plant derived compounds
themselves. Currently, the convention is to use purified compounds, thus relying on very
costly drug purification processes (194). Because we showed that whole plant A. annua
is more effective than a purified compound, we suggest testing the clinical efficacy of
whole plants, not simply their purified extracts. Using the whole plant directly, thereby
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maintaining its matrix of secondary metabolites, may have the added benefit of delaying
evolution of drug resistance as we’ve found here, thus saving many drugs from premature
obsolescence.
Second will be new approaches to plant breeding programs. Currently, breeding
programs are designed to create crops that yield increased concentration of a single
compound without regard to beneficial effects of many other plant constituents (211). We
suggest an alternative breeding strategy that selects plants for their optimal biologically
active phenotype. The goals would be to maintain the complex and diverse repertoire of
secondary metabolites and buffer associated synergies that require their co-isolation.
The third paradigm shift would be in the field of drug discovery. Current drug
discovery strategies most often follow simplistic models, testing activity of individual
purified compounds isolated from medicinal plants but ignoring synergism between plant
constituents(194). This archetypal approach neglects the effects of compounds that may
not show any activity when tested individually. Simple drug discover models were
exclude many important compounds from recognition because often the therapeutic does
exceed the toxicity dose of those single compounds. We suggest an alternative approach
that uses advanced computational and laboratory tools-- high-throughput screening to test
millions of combinations for potential antimicrobial activity-- to build complex
combinatorial models incorporating synergisms, antagonisms and other interactions
among plant components. More research is needed on the pharmacodynamics and
pharmacokinetics synergy, resistance reversal, and immunomodulation properties of
medicinal whole plants including toxicity studies and clinical research.
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